<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">61405</article-id><article-id pub-id-type="doi">10.7554/eLife.61405</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Cohesin mutations are synthetic lethal with stimulation of WNT signaling</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-203428"><name><surname>Chin</surname><given-names>Chue Vin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-144545"><name><surname>Antony</surname><given-names>Jisha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203429"><name><surname>Ketharnathan</surname><given-names>Sarada</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-217127"><name><surname>Labudina</surname><given-names>Anastasia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203433"><name><surname>Gimenez</surname><given-names>Gregory</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203432"><name><surname>Parsons</surname><given-names>Kate M</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203431"><name><surname>He</surname><given-names>Jinshu</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203430"><name><surname>George</surname><given-names>Amee J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0265-4476</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-217126"><name><surname>Pallotta</surname><given-names>Maria Michela</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-39116"><name><surname>Musio</surname><given-names>Antonio</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7701-6543</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-60139"><name><surname>Braithwaite</surname><given-names>Antony</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203434"><name><surname>Guilford</surname><given-names>Parry</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-89393"><name><surname>Hannan</surname><given-names>Ross D</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-199284"><name><surname>Horsfield</surname><given-names>Julia A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9536-7790</contrib-id><email>julia.horsfield@otago.ac.nz</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Pathology, Otago Medical School, University of Otago</institution><addr-line><named-content content-type="city">Dunedin</named-content></addr-line><country>New Zealand</country></aff><aff id="aff2"><label>2</label><institution>Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland</institution><addr-line><named-content content-type="city">Auckland</named-content></addr-line><country>New Zealand</country></aff><aff id="aff3"><label>3</label><institution>Genetics Otago Research Centre, University of Otago</institution><addr-line><named-content content-type="city">Dunedin</named-content></addr-line><country>New Zealand</country></aff><aff id="aff4"><label>4</label><institution>The John Curtin School of Medical Research, The Australian National University</institution><addr-line><named-content content-type="city">Canberra</named-content></addr-line><country>Australia</country></aff><aff id="aff5"><label>5</label><institution>Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche (CNR)</institution><addr-line><named-content content-type="city">Pisa</named-content></addr-line><country>Italy</country></aff><aff id="aff6"><label>6</label><institution>Department of Biochemistry, University of Otago</institution><addr-line><named-content content-type="city">Dunedin</named-content></addr-line><country>New Zealand</country></aff><aff id="aff7"><label>7</label><institution>Department of Biochemistry and Molecular Biology, University of Melbourne</institution><addr-line><named-content content-type="city">Parkville</named-content></addr-line><country>Australia</country></aff><aff id="aff8"><label>8</label><institution>Sir Peter MacCallum Department of Oncology, University of Melbourne</institution><addr-line><named-content content-type="city">Parkville</named-content></addr-line><country>Australia</country></aff><aff id="aff9"><label>9</label><institution>School of Biomedical Sciences, University of Queensland</institution><addr-line><named-content content-type="city">St Lucia</named-content></addr-line><country>Australia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Senior Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Majeti</surname><given-names>Ravi</given-names></name><role>Reviewing Editor</role><aff><institution>Stanford University</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>07</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e61405</elocation-id><history><date date-type="received" iso-8601-date="2020-07-24"><day>24</day><month>07</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-12-04"><day>04</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Chin et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Chin et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-61405-v2.pdf"/><abstract><p>Mutations in genes encoding subunits of the cohesin complex are common in several cancers, but may also expose druggable vulnerabilities. We generated isogenic MCF10A cell lines with deletion mutations of genes encoding cohesin subunits SMC3, RAD21, and STAG2 and screened for synthetic lethality with 3009 FDA-approved compounds. The screen identified several compounds that interfere with transcription, DNA damage repair and the cell cycle. Unexpectedly, one of the top âhitsâ was a GSK3 inhibitor, an agonist of Wnt signaling. We show that sensitivity to GSK3 inhibition is likely due to stabilization of Î²-catenin in cohesin-mutant cells, and that Wnt-responsive gene expression is highly sensitized in <italic>STAG2</italic>-mutant CMK leukemia cells. Moreover, Wnt activity is enhanced in zebrafish mutant for cohesin subunits <italic>stag2b</italic> and <italic>rad21</italic>. Our results suggest that cohesin mutations could progress oncogenesis by enhancing Wnt signaling, and that targeting the Wnt pathway may represent a novel therapeutic strategy for cohesin-mutant cancers.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cohesin</kwd><kwd>synthetic lethal</kwd><kwd>wnt signaling</kwd><kwd>drug screen</kwd><kwd>transcription</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001505</institution-id><institution>Health Research Council of New Zealand</institution></institution-wrap></funding-source><award-id>15/229</award-id><principal-award-recipient><name><surname>Horsfield</surname><given-names>Julia A</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001505</institution-id><institution>Health Research Council of New Zealand</institution></institution-wrap></funding-source><award-id>19/415</award-id><principal-award-recipient><name><surname>Hannan</surname><given-names>Ross D</given-names></name><name><surname>Horsfield</surname><given-names>Julia A</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005010</institution-id><institution>Associazione Italiana per la Ricerca sul Cancro</institution></institution-wrap></funding-source><award-id>IG23284</award-id><principal-award-recipient><name><surname>Musio</surname><given-names>Antonio</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>The Maurice Wilkins centre for Molecular Biodiscovery</institution></institution-wrap></funding-source><award-id>3705733</award-id><principal-award-recipient><name><surname>Antony</surname><given-names>Jisha</given-names></name><name><surname>Horsfield</surname><given-names>Julia A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Hypersensitivity of cohesin-deficient cells to Wnt signaling is concomitant with beta catenin stabilization and offers promise that Wnt agonists could be therapeutically effective in cohesin mutant cancers.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The cohesin complex is essential for sister chromatid cohesion, DNA replication, DNA repair, and genome organization. Three subunits, SMC1A, SMC3, and RAD21, form the core ring-shaped structure of human cohesin (<xref ref-type="bibr" rid="bib15">Dorsett and StrÃ¶m, 2012</xref>; <xref ref-type="bibr" rid="bib27">Horsfield et al., 2012</xref>). A fourth subunit of either STAG1 or STAG2 binds to cohesin by contacting RAD21 and SMC subunits (<xref ref-type="bibr" rid="bib61">Shi et al., 2020</xref>), and is required for the association of cohesin with DNA (<xref ref-type="bibr" rid="bib15">Dorsett and StrÃ¶m, 2012</xref>; <xref ref-type="bibr" rid="bib27">Horsfield et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Shi et al., 2020</xref>). The STAG subunits of cohesin are also capable of binding RNA in the nucleus (<xref ref-type="bibr" rid="bib50">Pan et al., 2020</xref>). Cohesin associates with DNA by interaction with loading factors NIPBL and MAU2 (<xref ref-type="bibr" rid="bib77">Wendt, 2017</xref>), its stability on DNA is regulated by the acetyltransferases ESCO1 (<xref ref-type="bibr" rid="bib80">Wutz et al., 2020</xref>) and ESCO2 (<xref ref-type="bibr" rid="bib69">van der Lelij et al., 2009</xref>), and its removal is facilitated by PDS5 and WAPL (<xref ref-type="bibr" rid="bib79">Wutz et al., 2017</xref>; <xref ref-type="bibr" rid="bib62">Shintomi and Hirano, 2009</xref>). The cohesin ring itself acts as a molecular motor to extrude DNA loops, and this activity is thought to underlie its ability to organize the genome (<xref ref-type="bibr" rid="bib71">Vian et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Mayerova et al., 2020</xref>). Cohesin works together with CCCTC-binding factor (CTCF) to mediate three-dimensional genome structures, including enhancer-promoter loops that instruct gene accessibility and expression (<xref ref-type="bibr" rid="bib23">Hansen, 2020</xref>; <xref ref-type="bibr" rid="bib58">Rowley and Corces, 2018</xref>). The consequences of cohesin mutation therefore manifest as chromosome segregation errors, DNA damage, and deficiencies in genome organization leading to gene expression changes.</p><p>All cohesin subunits are essential to life: homozygous mutations in genes encoding complex members are embryonic lethal (<xref ref-type="bibr" rid="bib27">Horsfield et al., 2012</xref>). However, haploinsufficient germline mutations in <italic>NIPBL</italic>, <italic>ESCO2</italic>, and in cohesin genes, cause human developmental syndromes known as the âcohesinopathiesâ (<xref ref-type="bibr" rid="bib27">Horsfield et al., 2012</xref>). Somatic mutations in cohesin genes are prevalent in several different types of cancer, including bladder cancer (15â40%), endometrial cancer (19%), glioblastoma (7%), Ewingâs sarcoma (16â22%) and myeloid leukemias (5â53%) (<xref ref-type="bibr" rid="bib14">De Koninck and Losada, 2016</xref>; <xref ref-type="bibr" rid="bib25">Hill et al., 2016</xref>; <xref ref-type="bibr" rid="bib74">Waldman, 2020</xref>). The prevalence of cohesin gene mutations in myeloid malignancies (<xref ref-type="bibr" rid="bib30">Kon et al., 2013</xref>; <xref ref-type="bibr" rid="bib51">Papaemmanuil et al., 2016</xref>; <xref ref-type="bibr" rid="bib66">Thol et al., 2014</xref>; <xref ref-type="bibr" rid="bib67">Thota et al., 2014</xref>; <xref ref-type="bibr" rid="bib82">Yoshida et al., 2013</xref>) reflects cohesinâs role in determining lineage identity and differentiation of hematopoietic cells (<xref ref-type="bibr" rid="bib19">Galeev et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Mazumdar et al., 2015</xref>; <xref ref-type="bibr" rid="bib45">Mullenders et al., 2015</xref>; <xref ref-type="bibr" rid="bib72">Viny et al., 2015</xref>). Of the cohesin genes, <italic>STAG2</italic> is the most frequently mutated, with about half of cohesin mutations in cancer involving <italic>STAG2</italic> (<xref ref-type="bibr" rid="bib74">Waldman, 2020</xref>).</p><p>While cancer-associated mutations in genes encoding RAD21, SMC3, and STAG1 are always heterozygous (<xref ref-type="bibr" rid="bib67">Thota et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Kon et al., 2013</xref>; <xref ref-type="bibr" rid="bib68">Tsai et al., 2017</xref>), mutations in the X chromosome-located genes <italic>SMC1A</italic> and <italic>STAG2</italic> can result in complete loss of function due to hemizygosity (males), or silencing of the wild type during X-inactivation (females). STAG2 and STAG1 have redundant roles in cell division, therefore complete loss of STAG2 is tolerated due to partial compensation by STAG1. Loss of both STAG2 and STAG1 leads to lethality (<xref ref-type="bibr" rid="bib7">Benedetti et al., 2017</xref>; <xref ref-type="bibr" rid="bib70">van der Lelij et al., 2017</xref>). STAG1 inhibition in cancer cells with STAG2 mutation causes chromosome segregation defects and subsequent lethality (<xref ref-type="bibr" rid="bib32">Liu et al., 2018</xref>). Therefore, although partial depletion of cohesin can confer a selective advantage to cancer cells, a complete block of cohesin function will cause cell death. The multiple roles of cohesin provide an opportunity to inhibit the growth of cohesin-mutant cancer cells via chemical interference with pathways that depend on normal cohesin function. For example, poly ADP-ribose polymerase (PARP) inhibitors were previously shown to exhibit synthetic lethality with cohesin mutations (<xref ref-type="bibr" rid="bib74">Waldman, 2020</xref>; <xref ref-type="bibr" rid="bib32">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Mondal et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">McLellan et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">O'Neil et al., 2013</xref>). PARP inhibitors prevent DNA double-strand break repair (<xref ref-type="bibr" rid="bib85">Zaremba and Curtin, 2007</xref>), a process that also relies on cohesin function.</p><p>To date, only a limited number of compounds have been identified as inhibitors of cohesin-mutant cells (<xref ref-type="bibr" rid="bib74">Waldman, 2020</xref>). Here, we sought to identify additional compounds of interest by screening libraries of FDA-approved molecules against isogenic MCF10A cells with deficiencies in RAD21, SMC3, or STAG2. Unexpectedly, our screen identified a novel sensitivity of cohesin-deficient cells to a GSK3 inhibitor that acts as an agonist of the Wnt signaling pathway. We found that Î²-catenin stabilization upon cohesin deficiency likely contributes to an acute sensitivity of Wnt target genes. The results raise the possibility that sensitization to Wnt signaling in cohesin-mutant cells may participate in oncogenesis, and suggest that Wnt agonism could be therapeutically useful for cohesin-mutant cancers.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Cohesin gene deletion in MCF10A cells results in minor cell cycle defects</title><p>To avoid any complications with pre-existing oncogenic mutations, we chose the relatively ânormalâ MCF10A line for creation and screening of isogenic deletion clones of cohesin genes <italic>SMC3</italic>, <italic>RAD21</italic>, and <italic>STAG2</italic>. MCF10A is a near-diploid, immortalized, breast epithelial cell line that exhibits normal epithelial characteristics (<xref ref-type="bibr" rid="bib64">Tait et al., 1990</xref>) and has been successfully used for siRNA and small molecule screening (<xref ref-type="bibr" rid="bib65">Telford et al., 2015</xref>). Two sgRNAs per gene were designed targeting the 5' and 3' UTR regions, respectively, of <italic>RAD21</italic>, <italic>SMC3,</italic> and <italic>STAG2</italic> genes. Single cells were isolated and grown into clones that were genotyped for complete gene deletions (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). We isolated several <italic>RAD21</italic> and <italic>SMC3</italic> deletion clones, and selected single clones for further characterization that grew normally and were essentially heterozygous. In the selected <italic>RAD21</italic> deletion clone, one of three <italic>RAD21</italic> alleles (on chromosome 8, triploid in MCF10A) was confirmed deleted, with one wild type and one undetermined allele. In the selected <italic>SMC3</italic> deletion clone, one of two <italic>SMC3</italic> alleles (on chromosome 10) was deleted. In the selected <italic>STAG2</italic> deletion clone, homozygous loss of <italic>STAG2</italic> was determined by the absence of STAG2 mRNA and protein. For convenience here, we named the three cohesin-mutant clones <italic>RAD21+/-</italic>, <italic>SMC3+/</italic>-,Â and <italic>STAG2-/-.</italic></p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Creation of MCF10A isogenic cell lines with cohesin gene deletions.</title><p>(<bold>A</bold>) Top, schematic diagram shows the deletion strategy for genes encoding cohesin subunits RAD21, SMC3, and STAG2 using two sgRNAs targeting the 5'UTR and the 3'UTR of each gene. Bottom, heterozygous clones were identified by PCR using specific primer pairs flanking the deletion region. Representative DNA gel shows the PCR products yielded using specific primer pairs for MCF10A parental and <italic>RAD21+/-</italic>Â deletion clone. M, ladder marker. (<bold>B,C,D</bold>) Schematic deletion strategy and summary of the allele sequences for the <italic>STAG2</italic> homozygous deletionÂ clone, and the <italic>RAD21</italic> and <italic>SMC3</italic> heterozygous deletionÂ clones. (<bold>E</bold>) RNA levels of the targeted genes in MCF10A cohesin-deficient clones. (<bold>F</bold>) Representative immunoblot and (<bold>G</bold>) quantification of cohesin protein levels. Î³-tubulin was used as loading control. nÂ =Â 3 independent experiments, meanÂ Â±s.d., one-tailed student <italic>t</italic> test: **pâ¤0.01; ****pâ¤0.0001. Guide RNAs and PCR primers can be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig1-v2.tif"/></fig><p>The <italic>RAD21+/-</italic>, <italic>SMC3+/</italic>-,Â and <italic>STAG2-/</italic>-Â clones had essentially normal cell cycle progression when compared to parental cells, although the <italic>RAD21</italic>+/-Â and <italic>SMC3</italic>+/-Â clones proliferated more slowly than the others (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>). Chromosome spreads revealed that only the <italic>STAG2</italic>-/-Â clone had noteworthy chromosome cohesion defects characterized by partial or complete loss of chromosome cohesion and gain or loss of more than one chromosome (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1A</xref>). Remarkably, <italic>SMC3+/</italic>-Â cells had noticeably larger nuclei that appeared to be less dense (<xref ref-type="fig" rid="fig2">Figure 2E,F</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1B</xref>), possibly owing to decompaction of DNA in this clone. <italic>RAD21+/</italic>-Â and <italic>SMC3+/</italic>-Â clones exhibited occasional lagging chromosomes and micronuclei, while the <italic>STAG2-/</italic>-Â clone did not (<xref ref-type="fig" rid="fig2">Figure 2G</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1CâE</xref>). Cell growth and morphology in monolayer culture was essentially normal in all three cohesin-mutant clones (<xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>minor deficiencies in cell cycle progression, chromosome segregation and nuclear morphology in cohesin-deficient isogenic cell lines.</title><p>(<bold>A</bold>) Proliferation curves of MCF10A parental and cohesin-deficient clones. nÂ =Â 3 independent experiments, meanÂ Â±Â sd, two-way ANOVA: **pâ¤0.01; ****pâ¤0.0001. Doubling times in hours of MCF10A parental cells are 15.5Â Â±Â 0.1; <italic>RAD21+/-</italic>, 17.1Â Â±Â 0.2; <italic>SMC3+/-</italic>, 21.4Â Â±Â 0.9; <italic>STAG2-/-</italic>, 16.4Â Â±Â 0.2 respectively. (<bold>B</bold>) Flow cytometry analysis of cell cycle progression. (<bold>C</bold>) Representative metaphase spread images of cohesin-deficient cells. Black arrow indicates a normal chromosome; Red arrow indicates premature chromatid separation (PCS). (<bold>D</bold>) Quantification of chromosome cohesion defects. A minimum of 20 metaphase spreads were examined per individual experiment, nÂ =Â 2 independent experiments, meanÂ Â±s.d. (<bold>E</bold>) Representative confocal images of nuclear morphology. Scale bar, 15 Î¼M. Yellow arrow indicates a micronucleus. (<bold>F</bold>) Quantification of nuclear area. (<bold>G</bold>) Quantification of micronuclei (MN). A minimum of 1000 cells was examined per individual experiment. nÂ =Â 5 independent experiments (square symbols), meanÂ Â±s.d., one-way ANOVA: *pâ¤0.05; ****pâ¤0.0001. Source data is available for A,D,F,G in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2âsource data 1</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2âsource data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig2">Figure 2a,d,f,g</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-61405-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 1.</label><caption><title>Cohesin deficiency causes a modest increase in chromosome mis-segregation events in MCF10A cells.</title><p>(<bold>A</bold>) Frequency of aneuploidy in cohesin-deficient MCF10A clones compared to parental MCF10A (WT). (<bold>B</bold>) Threshold compactness in the nuclei of cohesin-deficient clones compared to wild type MCF10A (R.U.Â =Â relative units). nÂ =Â 5 independent experiments (square symbols), meanÂ Â±Â s.d., one-way ANOVA: ***pâ¤0.001. (<bold>C</bold>) Representative images of abnormal interphase nuclei showing chromosome bridges, micronuclei, and lagging chromosomes at anaphase. (<bold>D</bold>) Quantification of chromosome bridges and micronuclei events in MCF10A cohesin-deficient cells. (<bold>E</bold>) Quantification of chromosome mis-segregation observed in MCF10A cohesin-deficient clones. At least 100 mitotic cells were examined per condition, nÂ =Â 3 independent experiments, meanÂ Â±s.d., one-way ANOVA **pâ¤0.01; ***pâ¤0.0005; ns, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 2.</label><caption><title>Cell morphology of MCF10A parental and cohesin-deficient cells grown at low and high confluence.</title><p>MCF10A cells were grown in low (1000 cells/well) and high density (4000 cells/well) in 96-well plates. Cohesin-deficient cells display a cobblestone-like morphology that is similar to MCF10A parental cells (WT). Scale bar, 250 Î¼M.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig2-figsupp2-v2.tif"/></fig></fig-group><p>Overall, the cohesin deletion clones appear to have infrequent but specific cell cycle anomalies that are shared between some, but not all clones. Anomalies include loss of chromosome cohesion, lagging chromosomes, or micronuclei, but these features do not appear to majorly impact on cell cycle progression or morphology.</p></sec><sec id="s2-2"><title>Cohesin-depleted cells have altered nucleolar morphology and are sensitive to DNA damaging agents</title><p>Cohesin-deficient cells have been demonstrated to display compromised nucleolar morphology and ribosome biogenesis (<xref ref-type="bibr" rid="bib8">Bose et al., 2012</xref>; <xref ref-type="bibr" rid="bib24">Harris et al., 2014</xref>), as well as sensitivity to DNA damaging agents (<xref ref-type="bibr" rid="bib5">Bailey et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Mondal et al., 2019</xref>). Analysis of our <italic>RAD21+/-</italic>, <italic>SMC3+/</italic>-,Â and <italic>STAG2-/</italic>-Â clones confirmed these findings. Cohesin-deleted cells in steady-state growth had abnormal nucleolar morphology, as revealed by fibrillarin and nucleolin staining (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>). Furthermore, we found that treatment with DNA intercalator/transcription inhibitor Actinomycin D caused marked fragmentation of nucleoli in all three cohesin-deficient cell lines as determined by fibrillarin staining (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>). Actinomycin D treatment increased Î³-H2AX and TP53 in the nuclei of <italic>RAD21+/</italic>-Â and <italic>SMC3+/</italic>-Â cells, in particular, indicating that these cells are compromised for DNA damage repair relative to the parental MCF10A cells (<xref ref-type="fig" rid="fig3">Figure 3CâF</xref>). In contrast, immunostaining for Î³-H2AX and TP53 levels were comparable at baseline between cohesin-deficient clones and parental cells. Interestingly, the <italic>STAG2-/</italic>-Â deletion clone was much more resistant to DNA damage caused by Actinomycin D (<xref ref-type="fig" rid="fig3">Figure 3CâF</xref>), even though nucleoli are abnormal in this clone (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Cohesin-deficient cells have increased sensitivity to nucleolar stress and DNA damaging agents.</title><p>(<bold>A</bold>) Representative image and (<bold>B</bold>) quantification of nucleolar dispersal observed in parental (WT) MCF10A cells and cohesin-deficient clones after exposure to a DNA damaging agent, Actinomycin D (ActD) 8 nM. Fibrillarin (FBL) staining was used as a marker for nucleoli. (<bold>C</bold>) Representative image and (<bold>D</bold>) quantification of DNA damage foci observed in parental (WT) MCF10A cells and cohesin-deficient clones after exposure to ActD. An antibody detecting Î³H2AX was used to visualize foci of DNA double-strand breaks. (<bold>E</bold>) Representative image and (<bold>F</bold>) quantification of nuclear p53 in parental (WT) MCF10A cells and cohesin-deficient clones after exposure to ActD. A minimum of 500 cells was examined per individual experiment. nÂ =Â 3 independent experiments, meanÂ Â±Â s.d., one-way ANOVA: *pâ¤0.05; **pâ¤0.01; ***pâ¤0.0005. Scale bar, 15 Î¼M. Source data is available for <xref ref-type="fig" rid="fig2">Figure 2B,D,F</xref> in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3âsource data 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3âsource data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-61405-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>Cohesin-deficient cells show altered nucleolar morphology.</title><p>(<bold>A</bold>) Representative images of nucleolar morphology as determined using fibrillarin (FBL) as a marker of nucleoli. (<bold>B,C</bold>) Quantification of FBL intensity and number of FBL spots per cell in each genotype. A minimum of 1000 cells was examined per individual experiment, nÂ =Â 3 independent experiments, meanÂ Â±Â s.d., one-way ANOVA: *pâ¤0.05; **pâ¤0.01; ***pâ¤0.0005. (<bold>D</bold>) Types of nucleolar morphology observed in MCF10A parental cells. (<bold>E</bold>) Representative images of nucleolar morphology determined by using nucleolin (NCL) as a marker. (<bold>F</bold>) Quantification of NCL intensity per cell in each genotype. At least 500 cells were examined per individual experiment, nÂ =Â 3 independent experiments, meanÂ Â±s.d., one-way ANOVA: **pâ¤0.01; ***pâ¤0.0005. (<bold>G</bold>) Quantification of NCL morphology classes present in cohesin-deficient cells. A.U., Arbitrary unit.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 2.</label><caption><title>PARP sensitivity of cohesin-deficient cells.</title><p>STAG2- and SMC3-deficient MCF10A cells show reduced viability following 48 hr of treatment with the PARP inhibitor, Olaparib, relative to parental cells (WT). nÂ =Â 2 independent experiments, meanÂ Â±s.d., one-way ANOVA: *pâ¤0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 3.</label><caption><title>Data replication with additional MCF10A isogenic cell lines with cohesin gene deletions.</title><p>(<bold>A</bold>) Summary of the allele sequences for additional <italic>RAD21</italic> and <italic>SMC3</italic> heterozygous clones, <italic>RAD21+/</italic>-Â clone two and <italic>SMC3+/</italic>-Â clone 2. (<bold>B</bold>) Cohesin-deficient clone 2 cells display a cobblestone-like morphology that is similar to MCF10A parental cells (WT). (<bold>C</bold>) RNA levels of the targeted genes in the additional MCF10A cohesin-deficient clones. (<bold>D</bold>) Quantification of chromosome cohesion defects in <italic>RAD21+/</italic>-Â clone two and <italic>SMC3+/</italic>-Â clone 2. A minimum of 20 metaphase spreads were examined per individual experiment, nÂ =Â 2 independent experiments, meanÂ Â±s.d. (<bold>E</bold>) Trypan blue measurement of cell viability for all cohesin-deficient clones in this study. Survival rates of mutant clones under standard culture conditions are not significantly different from wild type, nÂ =Â 2 independent experiments, meanÂ Â±s.d. (<bold>F</bold>) Proliferation curves of MCF10A parental and <italic>RAD21+/</italic>-Â clone two and <italic>SMC3+/</italic>-Â clone 2. (<bold>G</bold>) Dose-response curves were generated for validation of LY2090314 in <italic>RAD21+/</italic>-Â clone two and <italic>SMC3+/</italic>-Â clone two compared with MCF10A cells. For (<bold>F</bold>) and (<bold>G</bold>), nÂ =Â 3 independent experiments, meanÂ Â±Â sd, two-way ANOVA: *pâ¤0.05; **pâ¤0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig3-figsupp3-v2.tif"/></fig></fig-group><p>Overall, increased susceptibility of <italic>RAD21</italic>+/-Â and <italic>SMC3</italic>+/-Â clones to DNA damage is consistent with cohesinâs role in DNA double-strand break repair (<xref ref-type="bibr" rid="bib63">SjÃ¶gren and StrÃ¶m, 2010</xref>), and highlights the different requirements for RAD21 and SMC3 versus STAG2 in this process. Cohesin mutations were previously shown to sensitize cells to PARP inhibitor, Olaparib (<xref ref-type="bibr" rid="bib43">Mondal et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Matto et al., 2015</xref>). We confirmed a mild to moderate sensitivity to Olaparib in our cohesin-deficient MCF10A clones relative to parental cells (<xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>).</p><p>Collectively, characterization of our cohesin-deficient clones provided confidence that they represent suitable models for synthetic lethal screening. To confirm that the phenotypes of our chosen clones are representative, we selected a further two clones with heterozygous deletions in <italic>SMC3</italic> and <italic>RAD21</italic>, and monitored their growth, morphology and chromosome cohesion (<xref ref-type="fig" rid="fig3s3">Figure 3âfigure supplement 3</xref>). These analyses showed that the two additional deletion clones were similar to those already characterized (<xref ref-type="fig" rid="fig1">Figures 1</xref>â<xref ref-type="fig" rid="fig3">3</xref>), providing surety that our cohesin-deficient cell lines have properly representative phenotypes. Furthermore, none of the cohesin-deficient clones exhibited enhanced cell death compared with parental MCF10A cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>; <xref ref-type="fig" rid="fig3s3">Figure 3âfigure supplement 3</xref>).</p></sec><sec id="s2-3"><title>A synthetic lethal screen of FDA-approved compounds identifies common sensitivity of cohesin-mutant cells to WNT activation and BET inhibition</title><p>To identify additional compounds that inhibit the growth of cohesin-deficient cells, we screened the cohesin-deficient MCF10A cell lines with five dose concentrations (1â5000 nM) of 3009 compounds, including FDA-approved compounds (2399/3009), kinase inhibitors (429/3009), and epigenetic modifiers (181/3009) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). DMSO and Camptothecin were included as negative and positive viability controls, respectively (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>). We assayed cell viability after 48 hr of compound treatment.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>A synthetic lethal screen identifies common sensitivity of cohesin-deficient cells to WNT activation and BET inhibition.</title><p>(<bold>A</bold>) Schematic overview of the synthetic lethal screen. (<bold>B,C,D</bold>) Overview of the differential area over the curve (AOC) activity of all compounds tested in cohesin-deficient cell lines relative to parental MCF10A cells in the primary screen. A threshold of differential AOCÂ â¥Â 0.15 (red dashed lines) was used to filter candidate compounds of interest. (<bold>E</bold>) Venn diagram showing the number of common and unique compounds that inhibited <italic>RAD21+/-</italic>, <italic>SMC3+/</italic>-,Â and <italic>STAG2-/</italic>-Â in the primary screen. (<bold>F,G</bold>) Dose-response curves of I-BET-762 and LY2090314. Source data is available for BâE in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4âsource data 1</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4âsource data 1.</label><caption><title>Raw cell counts for SL screen compound treatments.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-61405-fig4-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4âsource data 2.</label><caption><title>Table and AOC measurements of all hit compounds from the screen.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-61405-fig4-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 1.</label><caption><title>Synthetic lethal screen controls.</title><p>(<bold>A</bold>) DMSO (negative control) and (<bold>B</bold>) Camptothecin (positive control) titrations were used to establish a cytotoxicity range in MCF10A cells and cohesin-deleted derivatives. nÂ =Â 2 independent experiments, meanÂ Â±s.d.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 2.</label><caption><title>Categories of compounds that differentially inhibit cohesin-deficient cells.</title><p>(<bold>A</bold>) Common and (<bold>B,C,D</bold>) unique categories of compounds identified in the primary screen. See <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4âsource data 1</xref> for details. (<bold>E,F</bold>) Dose-response curves were generated for validation of I-BET-762 and LY2090314 in MCF10A cells. (<bold>G</bold>) Dose-response curve of LY2090314 in the K562 STAG2R614* mutant cell line. Two-way ANOVA: ****pâ¤0.0001 Source data is available for <xref ref-type="fig" rid="fig4">Figure 4AâD</xref> in <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4âsource data 2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig4-figsupp2-v2.tif"/></fig></fig-group><p>Synthetic lethal candidate compounds were ranked based on the differential area over curve (AOC) values that are derived from a growth rate-based metric (GR) (<xref ref-type="fig" rid="fig4">Figure 4BâD</xref>; <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4âsource data 1</xref>). The GR metric takes into account the varying growth rate of dividing cells to mitigate inconsistent comparison of compound effects across cohesin-deficient cell lines (<xref ref-type="bibr" rid="bib22">Hafner et al., 2016</xref>). Compounds that causedÂ â¥30% growth inhibition in cohesin-deficient clones compared with parental MCF10A cells were selected for further analysis. The screen identified candidate 206 synthetic lethal compounds, of which 18 inhibited all three cohesin-deficient cell linesÂ â¥Â 30% more than the parental MCF10A cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>; <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4âsource data 2</xref>; <xref ref-type="table" rid="table1">Table 1</xref>; <xref ref-type="supplementary-material" rid="table1sdata1">Table 1âsource data 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Significant inhibitors of all three cohesin-deficient clones.</title><p><supplementary-material id="table1sdata1"><label>Table 1âsource data 1.</label><caption><title>Compounds with growth inhibitory activity (AOC) ranked to produce <xref ref-type="table" rid="table1">Table 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-61405-table1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="table1sdata2"><label>Table 1âsource data 2.</label><caption><title>Compounds effective in the secondary screen ranked to produce <xref ref-type="table" rid="table1">Table 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-61405-table1-data2-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top">Compound</th><th rowspan="2" valign="top">Rank 1Â° screen</th><th rowspan="2" valign="top">Rank 2Â° screen</th><th rowspan="2" valign="top">Target</th><th rowspan="2" valign="top">Pathway</th><th colspan="3" valign="top">1Â° differential AOC activity</th></tr><tr><th valign="top">â<italic>RAD21+/-</italic></th><th valign="top"><italic>SMC3+/-</italic></th><th valign="top"><italic>STAG2-/-</italic></th></tr></thead><tbody><tr><td valign="top">WAY-600</td><td valign="top">1</td><td valign="top">3</td><td valign="top">mTORC1/2</td><td valign="top">PI3K/AKT/mTOR</td><td valign="top">0.30</td><td valign="top">0.37</td><td valign="top">0.32</td></tr><tr><td valign="top">I-BET-762</td><td valign="top">2</td><td valign="top">8</td><td valign="top">BET proteins</td><td valign="top">Epigenetics</td><td valign="top">0.25</td><td valign="top">0.27</td><td valign="top">0.29</td></tr><tr><td valign="top">LY2090314</td><td valign="top">3</td><td valign="top">6</td><td valign="top">GSK3</td><td valign="top">WNT</td><td valign="top">0.25</td><td valign="top">0.22</td><td valign="top">0.25</td></tr><tr><td valign="top">Vistusertib (AZD2014)</td><td valign="top">4</td><td valign="top">1</td><td valign="top">mTORC1/2</td><td valign="top">PI3K/AKT/mTOR</td><td valign="top">0.18</td><td valign="top">0.33</td><td valign="top">0.26</td></tr><tr><td valign="top">P276-00</td><td valign="top">5</td><td valign="top">17</td><td valign="top">CDK1/4/9</td><td valign="top">Cell Cycle</td><td valign="top">0.17</td><td valign="top">0.29</td><td valign="top">0.28</td></tr><tr><td valign="top">MK-8745</td><td valign="top">6</td><td valign="top">22</td><td valign="top">Aurora A</td><td valign="top">Cell Cycle</td><td valign="top">0.18</td><td valign="top">0.30</td><td valign="top">0.26</td></tr><tr><td valign="top">Ethacridine lactate</td><td valign="top">7</td><td valign="top">28</td><td valign="top">Anti-infection</td><td valign="top">Microbiology</td><td valign="top">0.18</td><td valign="top">0.25</td><td valign="top">0.27</td></tr><tr><td valign="top">CUDC-101</td><td valign="top">8</td><td valign="top">36</td><td valign="top">EGFR, HDAC, HER2</td><td valign="top">Epigenetics</td><td valign="top">0.16</td><td valign="top">0.25</td><td valign="top">0.24</td></tr><tr><td valign="top">Dabrafenib (GSK2118436)</td><td valign="top">9</td><td valign="top">9</td><td valign="top">BRAF</td><td valign="top">MAPK</td><td valign="top">0.18</td><td valign="top">0.27</td><td valign="top">0.18</td></tr><tr><td valign="top">SAR131675</td><td valign="top">10</td><td valign="top">34</td><td valign="top">VEGFR3</td><td valign="top">Protein Tyrosine Kinase</td><td valign="top">0.15</td><td valign="top">0.17</td><td valign="top">0.33</td></tr><tr><td valign="top">ZM 447439</td><td valign="top">11</td><td valign="top">41</td><td valign="top">Aurora A/B</td><td valign="top">Cell Cycle</td><td valign="top">0.16</td><td valign="top">0.22</td><td valign="top">0.24</td></tr><tr><td valign="top">Gitoxigenin Diacetate</td><td valign="top">12</td><td valign="top">32</td><td valign="top">NA</td><td valign="top">Other</td><td valign="top">0.17</td><td valign="top">0.24</td><td valign="top">0.20</td></tr><tr><td valign="top">UNC669</td><td valign="top">13</td><td valign="top">62</td><td valign="top">Epigenetic Reader Domain</td><td valign="top">Epigenetics</td><td valign="top">0.18</td><td valign="top">0.23</td><td valign="top">0.20</td></tr><tr><td valign="top">4-Phenylbutyric Acid</td><td valign="top">14</td><td valign="top">29</td><td valign="top">Endoplasmic reticulum stress</td><td valign="top">Other</td><td valign="top">0.20</td><td valign="top">0.17</td><td valign="top">0.20</td></tr><tr><td valign="top">Ipatasertib (GDC-0068)</td><td valign="top">15</td><td valign="top">12</td><td valign="top">AKT</td><td valign="top">PI3K/AKT/mTOR</td><td valign="top">0.21</td><td valign="top">0.19</td><td valign="top">0.16</td></tr><tr><td valign="top">VX-702</td><td valign="top">16</td><td valign="top">43</td><td valign="top">P38 MAPK</td><td valign="top">MAPK</td><td valign="top">0.15</td><td valign="top">0.19</td><td valign="top">0.21</td></tr><tr><td valign="top">RVX-208</td><td valign="top">17</td><td valign="top">58</td><td valign="top">BET proteins</td><td valign="top">Epigenetics</td><td valign="top">0.16</td><td valign="top">0.20</td><td valign="top">0.17</td></tr><tr><td valign="top">Dihydroergotamine mesylate</td><td valign="top">18</td><td valign="top">49</td><td valign="top">NA</td><td valign="top">Other</td><td valign="top">0.16</td><td valign="top">0.19</td><td valign="top">0.16</td></tr><tr><td valign="top">Olaparib</td><td valign="top">351</td><td valign="top"/><td valign="top">PARP1/2</td><td valign="top">DNA Damage</td><td valign="top">0.11</td><td valign="top">0.13</td><td valign="top">0.22</td></tr></tbody></table></table-wrap><p>Most of the 206 compounds inhibited at least two cohesin-deficient cell lines and were classed in similar categories of inhibitor (<xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2AâD</xref>; <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4âsource data 2</xref>; <xref ref-type="table" rid="table1">Table 1</xref>). Of the 206 primary screen hits, 85 (including the 18 that inhibited all three cohesin-deficient clones, plus the most effective candidates from each inhibitor category) were subjected to secondary screening in an 11-point dose curve ranging from 0.5 nM to 10 Î¼M. Notable sensitive pathways included: DNA damage repair, the PI3K/AKT/mTOR pathway, epigenetic control of transcription, and stimulation of the Wnt signaling pathway (<xref ref-type="table" rid="table1">Table 1</xref>; <xref ref-type="supplementary-material" rid="table1sdata2">Table 1âsource data 2</xref>; <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4âsource data 2</xref>).</p><p>The identification of DNA damage repair inhibitors in our screen agrees with previous studies showing synthetic lethality of PARP inhibition with cohesin mutation (<xref ref-type="bibr" rid="bib41">McLellan et al., 2012</xref>). Differential sensitivity of the cohesin deletion cell lines to PI3K/AKT/mTOR inhibitors is consistent with the observed nucleolar deficiencies in cohesin-mutant cells (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>). The PI3K/AKT/mTOR pathway stimulates ribosome biogenesis and rDNA transcription; because rDNA is contained in nucleoli, it is likely that rDNA transcription and ribosome production is already compromised in the cohesin gene deletion cell lines. We had previously shown that BET inhibition is effective in blocking precocious gene expression in the chronic myelogenous leukemia cell line K562 containing a <italic>STAG2</italic> mutation (<xref ref-type="bibr" rid="bib2">Antony et al., 2020</xref>). Growth inhibition of cohesin-deficient MCF10A cells by I-BET-762 (<xref ref-type="fig" rid="fig4">Figure 4F</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2E</xref>) reinforces the idea that targeting BET could be therapeutically effective in cohesin-mutant cancers.</p><p>Interestingly, we found that LY2090314, a GSK3 inhibitor and stimulator of the Wnt signaling pathway, inhibits all three cohesin deletion lines (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig4">Figure 4G</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2F</xref>). LY2090314 also inhibited the growth of K562 STAG2 R614* mutant leukemia cells that we had previously characterized (<xref ref-type="bibr" rid="bib2">Antony et al., 2020</xref>;Â <xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2G</xref>) as well as the two additional MCF10A <italic>RAD21-</italic> and <italic>SMC3-</italic>deficient clones (<xref ref-type="fig" rid="fig3s3">Figure 3âfigure supplement 3G</xref>). Wnt signaling appears to act upstream of cohesin (<xref ref-type="bibr" rid="bib81">Xu et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">EstarÃ¡s et al., 2015</xref>), and also to be primarily downregulated downstream of cohesin mutation (<xref ref-type="bibr" rid="bib42">Mills et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Schuster et al., 2015</xref>; <xref ref-type="bibr" rid="bib4">Avagliano et al., 2017</xref>). Therefore, we were prompted to further investigate why Wnt stimulation via GSK3 inhibition might cause lethality in cohesin-deficient cells.</p></sec><sec id="s2-4"><title>Stabilization of Î²-catenin in cohesin-deficient MCF10A cells</title><p>In âoffâ state of canonical Wnt signaling, Î²-catenin forms a complex including Axin, APC, GSK3, and CK1 proteins. Î²-catenin phosphorylated by CK1 and GSK3 is recognized by the E3 ubiquitin ligase Î²-Trcp, which targets Î²-catenin for proteasomal degradation. Activation of Wnt signaling by ligand binding, or by GSK3 inhibition, releases Î²-catenin, allowing it to accumulate in the nucleus where it binds TCF to activate Wnt target gene transcription (<xref ref-type="bibr" rid="bib33">Logan and Nusse, 2004</xref>; <xref ref-type="bibr" rid="bib10">Clevers et al., 2014</xref>). We found that there was no difference in GSK3 levels between parental MCF10A cells and the cohesin-deficient clones, and upon treatment of cells with LY2090314, levels of GSK3 were reduced in all cells as expected (<xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>). In contrast, in untreated cells we found that Î²-catenin is stabilized in all three cohesin-deficient clones compared with parental MCF10A cells. When Wnt signaling is in the âoffâ state, phospho-Ser33/37/Thr41 marks Î²-catenin targeted for degradation. Membrane-associated phospho-Ser33/37/Thr41-Î²-catenin was increased in cohesin-deficient clones, and disappeared upon treatment with LY2090314 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Phospho-Ser675 Î²-catenin, the active form of Î²-catenin that is induced upon Wnt signaling, was noticeably increased in the cytoplasm of cohesin-deficient cells following treatment with LY2090314 (<xref ref-type="fig" rid="fig5">Figure 5B,C</xref>). The results imply that inactive Î²-catenin that would normally be targeted for degradation is instead stabilized in cohesin-deficient cells, and is available to be converted into the active form following inhibition of GSK3.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>LY2090314-mediated WNT stimulation leads to Î²-catenin stabilization in cohesin-deficient MCF10A cells.</title><p>(<bold>A</bold>) Immunoblot of the membrane fraction of parental (WT) and cohesin-deficient MCF10A cells shows increased basal level of Î²-catenin phosphorylation at Ser33/37/Thr41. (<bold>B</bold>) Immunoblot of the cytoplasmic fraction shows increased level of both total and phosphorylated Î²-catenin at Ser675 after parental (WT) and cohesin-deficient MCF10A cells were treated with LY2090314 at 100 nM for 24 hr. (<bold>C</bold>) Quantification of protein levels for total and phosphorylated Î²-catenin at Ser675. nÂ =Â 3 independent experiments, meanÂ Â±Â s.d., one-way ANOVA: *pâ¤0.05, **pâ¤0.01. (<bold>D</bold>) Immunofluorescence images show cytosolic accumulation of active Î²-catenin in cohesin-deficient MCF10A cells treated with LY2090314 100 nM for 24 hr, relative to parental (WT) MCF10A cells. White arrows indicate puncta of Î²-catenin (pSer675). Scale barÂ =Â 25 Î¼M. Full length blots and molecular size markers are available for A,B in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5âsource data 1</xref>. Source quantification data is available for C in <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5âsource data 2</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5âsource data 1.</label><caption><title>Untrimmed blots for <xref ref-type="fig" rid="fig5">Figure 5A, B</xref>.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-61405-fig5-data1-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5âsource data 2.</label><caption><title>Quantitation of blots in <xref ref-type="fig" rid="fig5">Figure 5A, B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-61405-fig5-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5âsource data 3.</label><caption><title>Untrimmed blots for <xref ref-type="fig" rid="fig5">Figure 5A, B</xref>.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-61405-fig5-data3-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5âsource data 4.</label><caption><title>Untrimmed blots forÂ <xref ref-type="fig" rid="fig5">Figure 5A, B</xref>.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-61405-fig5-data4-v2.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 1.</label><caption><title>GSK3 levels are unaffected in cohesin-deficient MCF10A cells.</title><p>Anti-GSK3 immunoblot of membrane fraction from parental MCF10A (WT) or cohesin-deficient cells treated with either DMSO or 100 nM LY2090314. (<bold>A</bold>) Membrane fraction after 6 hr of treatment with DMSO, or with LY2090314. (<bold>B</bold>) Cytoplasmic fraction after 6 hr of treatment with DMSO, or with LY2090314. Untrimmed blots and molecular size markers are available for A,B in <xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5âsource data 3</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 2.</label><caption><title>LY2090314-mediated WNT stimulation leads to increased Î²-catenin stabilization in SMC1A mutant HCT116 cells.</title><p>Unmodified HCT116 cells (WT), and cells modified to contain <italic>SMC1A</italic> mutations: SMC1AÂ (1), c.2027AÂ &gt;Â G; SMC1AÂ (2), c.2479 CÂ &gt;Â T, were treated with DMSO or LY2090314 at 100 nM for 24 hr. (<bold>A</bold>) Immunoblot of the membrane fraction of HCT116 wild type (WT) and <italic>SMC1A</italic> mutant-expressing HCT116 cells. The proteasome-targeted form of Î²-catenin phosphorylated at Ser33/37/Thr41 is slightly less abundant in the <italic>SMC1A</italic> mutants, and this phospho isoform is degraded in all cells following treatment with LY2090314. (<bold>B</bold>) Immunoblot of the cytoplasmic fraction shows increased basal level of phosphorylated Î²-catenin at Ser675 in the <italic>SMC1A</italic> mutant-expressing cells compared with HCT116 WT, and LY2090314 treatment markedly increased total Î²-catenin in the SMC1A mutants compared with HCT116 WT. Untrimmed blots and molecular size markers are available for A,B in <xref ref-type="supplementary-material" rid="fig5sdata4">Figure 5âsource data 4</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 3.</label><caption><title>WNT3A phenocopies LY2090314-mediated Î²-catenin accumulation in the cytoplasm.</title><p>Immunofluorescence images show that (<bold>A</bold>) parental MCF10A (WT) or cohesin-deficient cells treated with 0.5% DMSO have no Î²-catenin puncta. In contrast, 24 hr of treatment with both (<bold>B</bold>) LY2090314 and (<bold>C</bold>) WNT3A leads to formation of Î²-catenin puncta in the cytoplasm of cohesin-deficient cells (arrows), but not in parental MCF10A (WT) cells. Scale barÂ =Â 25 Âµm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig5-figsupp3-v2.tif"/></fig></fig-group><p>To determine if stabilization of Î²-catenin is conserved in a second model of cohesin-mutant cancer, we performed an identical LY2090314 treatment on HCT116 cells that were stably transfected to express two <italic>SMC1A</italic> mutations identified in human colorectal carcinomas, c.2027AÂ &gt;Â G (leading to p.E676G change near the hinge domain) and c.2479 CÂ &gt;Â T (leading to a truncated protein, p.Q827X) (<xref ref-type="bibr" rid="bib11">Cucco et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Sarogni et al., 2019</xref>). The limitation is that these cells are not a model of cohesin deficiency, but rather, one in which normal cohesin function is perturbed by expression of a mutant version of SMC1A (<xref ref-type="bibr" rid="bib59">Sarogni et al., 2019</xref>). We observed an increased basal level of phosphorylated Î²-catenin at Ser675 in cells that express either of these SMC1A mutants. Furthermore, LY2090314 treatment markedly increased total Î²-catenin in both the SMC1A mutants compared with HCT116 wild type controls (<xref ref-type="fig" rid="fig5s2">Figure 5âfigure supplement 2A,B</xref>). The results indicate that abnormally high levels of active Î²-catenin are also present following Wnt stimulation when a fourth subunit of cohesin, SMC1A, is perturbed.</p><p>Immunofluorescence labeling of MCF10A cells showed that in LY2090314-treated cells, the stabilized active phospho-Ser675 Î²-catenin (and total Î²-catenin, <xref ref-type="fig" rid="fig5s3">Figure 5âfigure supplement 3B</xref>) mainly locates to puncta in the cytoplasm (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). In contrast, no Î²-catenin accumulation was observed in DMSO-treated cells (<xref ref-type="fig" rid="fig5s3">Figure 5âfigure supplement 3A</xref>). Î²-catenin-containing puncta were also observed upon WNT3A treatment of cohesin-deficient clones (<xref ref-type="fig" rid="fig5s3">Figure 5âfigure supplement 3C</xref>). This indicates that Wnt stimulation rather than a secondary effect of LY2090314 is responsible for Î²-catenin accumulation. We could not reliably detect an increase of Î²-catenin in the nucleus of cohesin-deficient MCF10A clones by immunofluorescence (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), therefore we decided to use transcriptional response to determine the consequences of Î²-catenin stabilization for Wnt signaling.</p></sec><sec id="s2-5"><title>Cohesin-deficient leukemia cells are hypersensitive to Wnt signaling</title><p>RNA-sequencing analysis of the cohesin gene deletion clones compared with parental MCF10A cells revealed that gene expression changes strongly track with the identity of the deleted cohesin gene (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1A</xref>). However, expressed transcripts encoding Wnt signaling pathway components did not cluster differently in cohesin-deficient clones compared with parental MCF10A cells, and cohesin mutation-based clustering remained dominant (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1B</xref>). We reasoned that stimulation of Wnt signaling in a more responsive cell type might be necessary to determine how stabilized Î²-catenin in cohesin-deficient cells affects transcription.</p><p>Myeloid leukemias are frequently characterized by cohesin mutations, particularly in <italic>STAG2</italic>. Furthermore, activation of Wnt signaling is associated with transformation in AML (<xref ref-type="bibr" rid="bib75">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Beghini et al., 2012</xref>; <xref ref-type="bibr" rid="bib28">Kang et al., 2020</xref>) and AML patients were identified with mutations in <italic>AXIN1</italic> and <italic>APC</italic> that lead to stabilization of Î²-catenin (<xref ref-type="bibr" rid="bib17">Erbilgin et al., 2012</xref>). CMK is a Down Syndrome-derived megakaryoblastic cell line that typifies myeloid leukemias that are particularly prone to cohesin mutation (<xref ref-type="bibr" rid="bib82">Yoshida et al., 2013</xref>). We edited CMK to contain the STAG2-AML associated mutation R614* (<xref ref-type="bibr" rid="bib2">Antony et al., 2020</xref>) and selected single clones with complete loss of the STAG2 protein to create the cell line CMK-<italic>STAG2-/-</italic> (<xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2AâC</xref>).</p><p>Immunofluorescence showed that Î²-catenin is increased by 20% in the nuclei of CMK<italic>-STAG2-/</italic>-Â cells relative to parental cells upon WNT3A stimulation (<xref ref-type="fig" rid="fig6">Figure 6A,B</xref>). To determine immediate early transcriptional responses to Wnt signaling, RNA-sequencing was performed on CMK-<italic>STAG2-/</italic>-Â and parental CMK cells at baseline and after stimulation with WNT3A for 4 hr. Around 76% more genes were upregulated in response to WNT3A in CMK-<italic>STAG2-/</italic>-Â compared with CMK parental cells (616 in CMK-<italic>STAG2-/</italic>-Â vs 350 in CMK parental, FDRÂ â¤Â 0.05, <xref ref-type="fig" rid="fig6">Figure 6C</xref>), while around the same number were downregulated. About one quarter of differentially expressed genes overlapped between CMK-<italic>STAG2-/</italic>-Â and CMK parental cells.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Cohesin-STAG2 mutant CMK cells show increased sensitivity to Wnt signaling.</title><p>(<bold>A</bold>) Immunofluorescence images showing slightly increased nuclear accumulation of Î²-catenin in STAG2-CMK cells (<italic>STAG2-/-</italic>) compared to parental (WT) following treatment with LY2090314 at 100 nM for 24 hr. (<bold>B</bold>) Quantification of nuclear total Î²-catenin in parental (WT) and STAG2-CMK cells (<italic>STAG2-/-</italic>) cells. Fluorescence of nuclear total Î²-catenin was determined relative to the nuclear area. Image J was used quantify cells from 10 different confocal fields. The graph depicts s.e.m. from analyses of 170â188 cell nuclei, and the p value was calculated using a studentâs <italic>t</italic> test. (<bold>C</bold>) Histogram showing the number of genes upregulated or downregulated at FDRÂ â¤Â 0.05 upon WNT3A treatment in parental (WT) and <italic>STAG2-</italic>/-Â CMK cells. WNT3A stimulation was performed on three biological replicates, from three independent experiments. (<bold>D</bold>) Overlap of genes significantly upregulated or downregulated (FDRÂ â¤Â 0.05) upon WNT3A treatment between parental (WT) and <italic>STAG2-/-</italic>Â CMK cells. (<bold>E</bold>) Top enriched pathways (ranked by gene count) from the significantly downregulated and upregulated genes (FDRÂ â¤Â 0.05) following WNT3A treatment in <italic>STAG2-/</italic>-Â and parental (WT) CMK cells using the ClusterProfiler R package on theÂ Gene Ontology Biological Process dataset modeling for both cell types (WT or <italic>STAG2-/-</italic>) and regulation pattern (up- or downregulation). Source data is available for C,D in <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6âsource data 1</xref>.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6âsource data 1.</label><caption><title>Gene expression data for <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-61405-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 1.</label><caption><title>RNA-sequencing profiling of cohesin-deficient MCF10A cells.</title><p>(<bold>A</bold>) Whole genome correlation matrix of MCF10A cells. The dendrogram shows a common clustering of the biological replicates. There are two main clusters. The <italic>STAG2-/-</italic> (MT10_1â3) transcriptomes are more similar to the WT (MWT_1â3). <italic>SMC3+/-</italic> (MS_1â3) and <italic>RAD21+/-</italic> (MR50_1â3) populate the second cluster. (<bold>B</bold>) MCF10A gene expression profile of genes involved in WNT signaling pathways according to Gene Ontology annotation (GO:0016055). The heatmap shows the clustering of the scaled (z-score) normalized count (log2RPKM) for each replicate. RNA-sequencing data is available in the GEO database under GSE154086.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 2.</label><caption><title>Enhanced sensitivity of cohesin-mutant CMK cells to Wnt stimulation.</title><p>(<bold>A</bold>) Sanger sequencing shows successful CRISPR-CAS9 editing introducing the <italic>STAG2</italic> R614* CÂ &gt;Â T mutation site into CMK cells. (<bold>B</bold>) Reduced STAG2 mRNA and (<bold>C</bold>) protein in <italic>STAG2-/</italic>-Â CMK cells. (<bold>D</bold>) Heatmap showing log2 RPKM values of 402 genes upregulated only in <italic>STAG2</italic> mutant cells (FDRÂ â¤Â 0.05) following 4 hr of WNT3A treatment. (<bold>E</bold>) GSEA analyses of the 402 upregulated genes. (<bold>F</bold>) Heatmap showing log2 RPKM values of 171 genes downregulated only in <italic>STAG2</italic> mutant cells (FDRÂ â¤Â 0.05) following 4 hr of WNT3A treatment. (<bold>G</bold>) GSEA analyses of the 171 genes significantly downregulated only in the <italic>STAG2</italic> mutant line. Gene lists are provided in <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6âsource data 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig6-figsupp2-v2.tif"/></fig></fig-group><p>Strikingly, 402 genes that were not Wnt-responsive in CMK parental cells became Wnt-responsive upon introduction of the <italic>STAG2</italic> R614* mutation (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Genes upregulated in CMK-<italic>STAG2-/</italic>-Â markedly increased the number of Wnt-sensitive biological pathways following WNT3A treatment compared with parental CMK cells (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). A strongly upregulated cluster of 244 transcripts in CMK-<italic>STAG2-/</italic>-Â included genes encoding signaling molecules (JAG2, IL6ST, SEMA3G) and transcription factors (SP7, KLF3, SMAD3, EP300, and EPHA4) (<xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2D</xref>). Genes in this cluster were enriched for LEF1 and TCF7 binding sites,Â indicating their potential to be directly regulated by Î²-catenin. Enriched biological pathways included Wnt signaling, cell cycle and metabolism (<xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2E</xref>). Pathway analyses of genes significantly downregulated only in CMK-<italic>STAG2-/</italic>-Â also showed enrichment for metabolism (<xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2F,G</xref>).</p><p>Overall, our results show that CMK-<italic>STAG2-/</italic>-Â cells are exquisitely sensitive to Wnt signaling. Introduction of the <italic>STAG2</italic> R614* mutation amplified expression of Wnt-responsive genes and sensitized genes and pathways that are not normally Wnt-responsive in CMK. This sensitivity could be due at least in part to stabilized Î²-catenin.</p></sec><sec id="s2-6"><title>Conservation of WNT sensitivity in cohesin-deficient zebrafish</title><p>To determine if enhanced Wnt sensitivity is conserved in a cohesin-deficient animal model, we used two previously described zebrafish cohesin mutants: <italic>stag2b</italic><sup>nz207</sup> (<xref ref-type="bibr" rid="bib29">Ketharnathan et al., 2020</xref>), which has a seven base-pair deletion in <italic>stag2b</italic> leading to a prematurely truncated Stag2b protein, and <italic>rad21</italic><sup>nz171</sup> (<xref ref-type="bibr" rid="bib26">Horsfield et al., 2007</xref>), which has a nonsense point mutation in the <italic>rad21</italic> gene that eliminates Rad21 protein. To provide a readout for Wnt signaling, we used transgenic zebrafish carrying a TCF/Î²-catenin reporter in which exogenous Wnt stimulation induces nuclear mCherry: <italic>Tg(7xTCF-Xla.Siam:nslmCherry)<sup>ia5</sup></italic> (<xref ref-type="bibr" rid="bib44">Moro et al., 2012</xref>). The Wnt reporter construct, which drives nuclear mCherry red fluorescence in Wnt-responsive cells, was introduced into zebrafish carrying the <italic>stag2b</italic><sup>nz207</sup> and <italic>rad21</italic><sup>nz171</sup> mutation by crossing.</p><p>Zebrafish embryos heterozygous for <italic>Tg(7xTCF-Xla.Siam:nslmCherry)<sup>ia5</sup></italic>, and either homozygous for <italic>stag2b</italic><sup>nz207</sup>, <italic>rad21</italic><sup>nz171</sup>,Â or wild type, were exposed to 0.15 M LiCl, an agonist of the Wnt signaling pathway (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Expression of mCherry in the midbrain of embryos was detected at 20 hr post-fertilization (hpf) by epifluorescence and confocal imaging. A constitutive low level of mCherry is present in the developing midbrain of both untreated wild type (<xref ref-type="fig" rid="fig7">Figure 7A,B,I,J</xref>), and <italic>rad21</italic><sup>nz171</sup> embryos (<xref ref-type="fig" rid="fig7">Figure 7M,N</xref>). On the other hand, untreated <italic>stag2b</italic><sup>nz207</sup> embryos exhibited noticeably higher basal mCherry levels than wild type siblings (<xref ref-type="fig" rid="fig7">Figure 7E,F</xref> compared with A,B). This observation indicates that the Wnt pathway is more intrinsically active in these embryos. However, the addition of LiCl did not result in much additional fluorescence owing to <italic>stag2b</italic><sup>nz207</sup> mutation (<xref ref-type="fig" rid="fig7">Figure 7G,H</xref> compared with C,D). While mCherry expression in <italic>rad21</italic><sup>nz171</sup> mutants resembled that in wild type embryos at baseline, LiCl treatment dramatically increased the existing midbrain mCherry expression in <italic>rad21</italic><sup>nz171</sup> mutants compared with wild type embryos (<xref ref-type="fig" rid="fig7">Figure 7O,P</xref> compared with K,L). This observation indicates that <italic>rad21</italic><sup>nz171</sup> mutants are more sensitive to Wnt stimulation than wild type.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Zebrafish <italic>stag2b</italic> and <italic>rad21</italic> cohesin mutants show increased sensitivity to Wnt signaling.</title><p>Wnt reporter <italic>Tg(7xTCF-Xla.Siam:nlsmCherry)<sup>ia5</sup></italic> control embryos, <italic>Tg(7xTCF-Xla.Siam:nlsmCherry)<sup>ia5</sup>;stag2b<sup>nz207</sup></italic> and <italic>Tg(7xTCF-Xla.Siam:nlsmCherry)<sup>ia5</sup>;rad21<sup>nz171</sup></italic> cohesin-mutant embryos were treated with 0.15 M LiCl from 4 hpf to 20 hpf. (<bold>AâH</bold>) max projections of 4 (10 Î¼m) optical sections. (<bold>A,C,E,G</bold>) TD (transmitted light detector) images merged with confocal images. (<bold>B,D,F,H</bold>) confocal images alone. (<bold>I,K,M,O</bold>) Brightfield/fluorescent and (<bold>J,N,L,P</bold>) <bold>c</bold>onfocal images of the same embryos in I,K,M,O. (<bold>AâD</bold>) and (<bold>IâJ</bold>) <italic>Tg(7xTCF-Xla.Siam:nlsmCherry)<sup>ia5</sup></italic> control embryos (WT) have low level fluorescence (Wnt reporter activity) in the midbrain that is increased following treatment. (<bold>EâH</bold>) <italic>Tg(7xTCF-Xla.Siam:nlsmCherry)<sup>ia5</sup>; stag2b<sup>nz207</sup></italic> embryos have elevated baseline levels of fluorescence (Wnt reporter activity) relative to controls (yellow arrow) with not much further increase upon LiCl treatment. (<bold>MâP</bold>) <italic>Tg(7xTCF-Xla.Siam:nlsmCherry)<sup>ia5</sup>; rad21<sup>nz171</sup></italic> cohesin-mutant embryos show enhanced Wnt reporter activity in the midbrain (green arrow) upon LiCl treatment, relative to controls. hpf, hours post-fertilization. mb, midbrain. Scale bar, 50 Âµm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61405-fig7-v2.tif"/></fig><p>Overall, the results show that Wnt signaling is sensitized in cohesin-mutant zebrafish embryos, similar to our observations in MCF10A and CMK cell lines. Our findings agree with previous work showing that canonical Wnt signaling is hyperactivated in cohesin-loader <italic>nipblb</italic>-loss-of-function zebrafish embryos (<xref ref-type="bibr" rid="bib40">Mazzola et al., 2019</xref>). Altogether, the results suggest that hyperactivation of Wnt signaling is a conserved feature of cohesin-deficient cells, and that enhanced sensitivity to Wnt is at least in part due to stabilization of Î²-catenin.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The cohesin complex and its regulators are encoded by several different loci, and genetic alterations in any one of them may occur in up to 26% of patients included in The Cancer Genome Atlas (TCGA) studies (<xref ref-type="bibr" rid="bib57">Romero-PÃ©rez et al., 2019</xref>). Therefore, we were motivated to identify compounds that interfere with cell viability in more than just one type of cohesin mutant. The generation of <italic>RAD21</italic>, <italic>SMC3,</italic> and <italic>STAG2</italic> cohesin mutations in the breast epithelial cell line MCF10A resulted in mild cell cycle and nucleolar phenotypes that are consistent with the many cellular roles of cohesin. Differences between <italic>RAD21</italic> and <italic>SMC3</italic> heterozygotes vs <italic>STAG2</italic> homozygotes could be explained by the fact that RAD21 and SMC3 are obligate members of the cohesin ring, whereas STAG2 can be compensated by STAG1.</p><p>Synthetic lethal sensitivities of cohesin-mutant cells that emerged from our screen mostly related to the phenotypes of cohesin-mutant cells, and/or their previously identified vulnerabilities. For example, cohesin-mutant cells were sensitive to inhibitors of the PI3K/Akt/mTOR pathway that feeds into ribosome biogenesis, epigenetic inhibitors that could interfere with cohesinâs genome organization and gene expression roles, and a limited sensitivity to PARP inhibitors. The observed sensitivity to PI3K/AKT/mTOR inhibitors is consistent with the nucleolar disruption present in cohesin-deficient cell lines, and with cohesinâs known involvement in rDNA transcription and ribosome biogenesis (<xref ref-type="bibr" rid="bib8">Bose et al., 2012</xref>). We have also previously described evidence for sensitivity of cohesin-deficient cell lines to bromodomain (BET) inhibition (<xref ref-type="bibr" rid="bib2">Antony et al., 2020</xref>). However, the Wnt agonist LY2090314, which mimics Wnt activation by inhibiting GSK3-Î² (<xref ref-type="bibr" rid="bib3">Atkinson et al., 2015</xref>), emerged as a novel class of compound that inhibited the growth of all three cohesin mutants tested. Because there is pathway convergence between Wnt signaling and the PI3K/AKT/mTOR pathway (<xref ref-type="bibr" rid="bib54">Prossomariti et al., 2020</xref>) it is possible that these pathways represent a common avenue of sensitivity. The identification of PI3K/AKT/mTOR inhibitors in the screen supports this notion.</p><p>Wnt signals are important for stem cell maintenance and renewal in multiple mammalian tissues (<xref ref-type="bibr" rid="bib10">Clevers et al., 2014</xref>). Canonical Wnt signaling is required for self-renewal of leukemia stem cells (LSCs) (<xref ref-type="bibr" rid="bib28">Kang et al., 2020</xref>), and is reactivated in more differentiated granulocyte-macrophage progenitors (GMPs) when they give rise to LSCs (<xref ref-type="bibr" rid="bib75">Wang et al., 2010</xref>). Wnt signaling is an important regulator of hematopoietic stem cell (HSC) self-renewal as well (<xref ref-type="bibr" rid="bib56">Rattis et al., 2004</xref>). Our results suggest that cohesin-deficient cells are sensitive to Wnt agonism because they already have stabilization of Î²-catenin. Interestingly, multiple experimental systems showed that dose-dependent reduction in cohesin function causes HSC expansion accompanied by a block in differentiation (<xref ref-type="bibr" rid="bib73">Viny and Levine, 2018</xref>; <xref ref-type="bibr" rid="bib39">Mazumdar and Majeti, 2017</xref>). It is possible that the effects of cohesin deficiency on HSC development could be in part due to enhanced Wnt signaling.</p><p>Cohesin mutations are particularly frequent (53%) in Down Syndrome-associated Acute Megakaryoblastic Leukemia (DS-AMKL) patients (<xref ref-type="bibr" rid="bib82">Yoshida et al., 2013</xref>). In the edited DS-AMKL cell line <italic>STAG2</italic>-CMK, there was a dramatically enhanced immediate early transcriptional response to WNT3A, including induction of hundreds of genes that are not normally responsive to WNT3A in this cell line. It is possible that STAG2 deficiency in CMK leads to an altered chromatin structure that sensitizes genes to Wnt signaling. However, we observed increased nuclear localization of Î²-catenin in <italic>STAG2</italic>-CMK, increasing the likelihood that stabilization of Î²-catenin in <italic>STAG2</italic>-CMK cells accounts at least in part for amplified gene expression in response to WNT3A. Interestingly, DS-AMKL leukemias are often associated with amplified Wnt signaling caused by Trisomy 21 (<xref ref-type="bibr" rid="bib16">Emmrich et al., 2014</xref>) suggesting a possible synergy between cohesin mutations and Wnt signaling dysregulation in DS-AMKL.</p><p>We observed an enhanced Wnt reporter response to Wnt activation in <italic>rad21-</italic> andÂ <italic>stag2b</italic>-mutant zebrafish, arguing that Wnt sensitivity upon cohesin mutation is a conserved phenomenon. Previous research shows that cohesin genes are at once both targets (<xref ref-type="bibr" rid="bib81">Xu et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Ghiselli et al., 2003</xref>) and upstream regulators (<xref ref-type="bibr" rid="bib18">EstarÃ¡s et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Schuster et al., 2015</xref>; <xref ref-type="bibr" rid="bib4">Avagliano et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Mazzola et al., 2019</xref>) of Wnt signaling. For example, depletion of cohesin-loader <italic>nipbl</italic> in zebrafish embryos was reported to downregulate Wnt signaling at 24 hpf (<xref ref-type="bibr" rid="bib53">Pistocchi et al., 2013</xref>), but to upregulate it at 48 hpf (<xref ref-type="bibr" rid="bib40">Mazzola et al., 2019</xref>). What determines the directionality of cohesinâs effect on Wnt signaling is unclear. It is possible that feedback loops operate differently in cell- and signal-dependent contexts (<xref ref-type="bibr" rid="bib35">MacDonald et al., 2009</xref>) in cohesin-deficient backgrounds.</p><p>Is Wnt pathway activation a conserved feature of cohesin-mutant cancers? Using publicly available data at TCGA (<xref ref-type="bibr" rid="bib21">Grossman et al., 2016</xref>), we correlated expression of genes in the Wnt pathway (Hallmark WNT Î²-catenin signaling) with nonsense mutation of <italic>STAG2</italic>, the most common of the cohesin mutations, in the four most represented cancers (bladder cancer, endometrial carcinoma, glioblastoma multiforme and cervical kidney renal papillary cell carcinoma). In comparative ranking, the Wnt pathway ranks 8<sup>th</sup> for enrichment in upregulated genes (after DNA repair/G2 checkpoint, MYC/E2F targets, oxidative phosphorylation and the unfolded protein response; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). While our analysis could indicate conserved upregulation of the Wnt pathway in <italic>STAG2</italic> mutant cancers, a caveat is that the true situation is likely to be more complex. If Î²-catenin is stabilized, upstream and in-parallel effectors such as Wnt ligands, receptors, signaling intermediates might trend to downregulation owing to negative feedback loop regulation of the Wnt pathway for example via DKK1 (<xref ref-type="bibr" rid="bib46">Niida et al., 2004</xref>). Furthermore, because cancer collections are unlikely to be under Wnt stimulation at the time of RNA collection, it is possible that their true Wnt sensitivity will be missed in a steady-state transcription analysis.</p><p>A remaining question is exactly what causes Î²-catenin stabilization and Wnt hyperactivation in cohesin-mutant cells. One possibility is that stabilization of Î²-catenin upon cohesin deficiency is linked to energy metabolism. For example, in developing amniote embryos, glycolysis in actively growing cells of the embryonic tail bud raises the intracellular pH, which in turn causes Î²-catenin stabilization (<xref ref-type="bibr" rid="bib49">Oginuma et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Oginuma et al., 2017</xref>). This mode of glycolysis is similar to that observed in cancer cells and is known as the Warburg effect (<xref ref-type="bibr" rid="bib52">Parks et al., 2013</xref>; <xref ref-type="bibr" rid="bib76">Wang et al., 2016</xref>). Metabolic and oxidative stress disturbances in cohesin-mutant cells observed in this study and others (<xref ref-type="bibr" rid="bib8">Bose et al., 2012</xref>; <xref ref-type="bibr" rid="bib12">Cukrov et al., 2018</xref>) might similarly influence Î²-catenin stability and in turn, sensitivity to incoming Wnt signals. Further research will be needed to determine how Î²-catenin is stabilized in cohesin-deficient cells, whether Î²-catenin stabilization is part of a transition to malignancy, and if the associated Wnt sensitivity represents a therapeutic opportunity in cohesin-mutant cancers.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture</title><p>MCF10A (a spontaneously immortalized breast epithelial cell line) was purchased from Sigma (product #: CRL 10317). Sigma use STR analysis to verify the line. A PCR test in our laboratory showed that all cells were mycoplasma free. CMK (acute megakaryocytic leukemia associated with Down Syndrome) was a gift from Dr Motomi Osato, National University of Singapore. These cells tested negative with MycoAlert Mycoplasma Detection Kit in our laboratory. K562 (chronic myelogenous leukemia) were purchased from ATCC, CCL-243. These cells tested mycoplasma free using B3903-Mycoplasma Detection Kit - QuickTest-com from Biotool. The HTC116 cell line was purchased form ATCC. STR analysis is used by ATCC to verify all cell lines.</p><p>MCF10A and its cohesin-deficient derivatives were maintained in Dulbeccoâs modified Eagle medium (DMEM) (Life Technologies) supplemented with 5% horse serum (Life Technologies), 20 ng/mL of epidermal growth factor (EGF) (Peprotech), 0.5 mg/mL of hydrocortisone, 100 ng/mL of cholera toxin and 10 Î¼g/mL of insulin (local pharmacy). All supplements were purchased from Sigma-Aldrich unless otherwise stated. K562 cells were maintained in Isocoveâs Modified Dulbeccoâs Media (IMDM) (Life Technologies) containing 10% fetal bovine serum. CMK cells were maintained in RPMI 1640 media containing 10% fetal bovine serum. CMK cells and adherent K562-<italic>STAG2</italic> null line were detached for subculture using trypsin-EDTA (0.005% final concentration, Life Technologies). For WNT stimulation, recombinant Human WNT-3A Protein (5036-WN, R and D systems) was used at 200 ng/mL for 4 hr. Human colorectal carcinoma HCT116 cells were grown in DMEM with 10% fetal calf serum and antibiotics. Stable transfection of HCT116 cells with <italic>SMC1A</italic> mutations c.2027AÂ &gt;Â G and c.2479 CÂ &gt;Â T was described previously (<xref ref-type="bibr" rid="bib59">Sarogni et al., 2019</xref>). All cells were cultured at 37Â°C in 5% CO<sub>2</sub>.</p></sec><sec id="s4-2"><title>Generation of isogenic cell lines using CRISPR-CAS9 editing</title><p>We used CRISPR-CAS9 sgRNAs targeting the 5' and 3' UTR regions of <italic>RAD21</italic>, <italic>SMC3</italic> and <italic>STAG2</italic> gene to create MCF10A <italic>RAD21+/-,</italic> MCF10A <italic>SMC3+/-</italic>, and MCF10A <italic>STAG2-/-</italic>. Specific sgRNAs were cloned into the px458 plasmid (<xref ref-type="bibr" rid="bib55">Ran et al., 2013</xref>) and transfected into MCF10A cells. Single GFP-positive cells were isolated into 96-well plates using a FACSAriaII (Becton Dickinson) and clonally expanded. PCR screening and Sanger sequencing identified cells with heterozygous deletion of <italic>RAD21</italic> or <italic>SMC3</italic> and homozygous deletion of <italic>STAG2</italic>. Primer and guide sequences are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Editing of K562 to create STAG2 R614* mutation has been described previously (<xref ref-type="bibr" rid="bib2">Antony et al., 2020</xref>). The CMK line with the STAG2 R614* mutation was generated using the same sgRNA and method.</p></sec><sec id="s4-3"><title>Quantitative PCR (RT-qPCR)</title><p>Total RNA was extracted using NucleoSpin RNA kit (Machery-Nagel). cDNA was synthesized using qScript cDNA SuperMix (Quanta Biosciences). RT-qPCR was performed on a LightCycler 480 II (Roche Life Science) using SYBR Premix Ex Taq (Takara). Expression values relative to reference genes <italic>cyclophilin</italic> and <italic>glyceraldehyde 3-phosphate dehydrogenase</italic> (<italic>GAPDH</italic>) were derived using qBase Plus (Biogazelle). Primer sequences are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-4"><title>Antibodies</title><p>Primary antibodies used are as follows: anti-RAD21 (ab992), anti-SMC3 (#5696, CST), anti-STAG2 (ab4463), anti-Î³-Tubulin (T5326; Sigma-Aldrich) in 1:5000, anti-fibrillarin (ab5821), anti-nucleolin (ab13541), anti-gamma H2AX (ab26350), anti-TP53 (ab131442), anti-Î²-catenin (#9562, CST), anti-phospho-Î²-catenin (Ser675) (#9567, CST), anti-phospho- phospho-Î²-catenin (Ser33/37/Thr41) (#9561, CST). Secondary antibodies used for immunofluorescence were anti-mouse Alexa Fluor 488 (1:2000, Life Technologies), anti-rabbit Alexa Fluor 488Â (1:2000, Life Technologies),Â anti-rabbit Alexa Fluor 568 (1:2000, Life Technologies). All antibodies were used in 1:1000 for immunoblotting or immunofluorescence unless otherwise stated.</p></sec><sec id="s4-5"><title>Immunoblotting</title><p>Immunoblotting was performed as described previously (<xref ref-type="bibr" rid="bib1">Antony et al., 2015</xref>; <xref ref-type="bibr" rid="bib13">Dasgupta et al., 2016</xref>). Primary antibodies were detected using IRDye 800CW Donkey anti-Goat IgG and IRDye 680CW Goat anti-mouse IgG, IRDye 800CW Goat anti-rabbit IgG (LICOR). LI-COR Odyssey and LI-COR Image Studio software was used to image and quantify blots.</p></sec><sec id="s4-6"><title>Proliferation assays</title><p>MCF10A parental and isogenic cohesin-deficient cell lines were seeded in 96-well plates at 2000 cells per well. Cell confluence was monitored by time-lapse microscopy using IncuCyte FLR with a 10X objective for 5 days.</p></sec><sec id="s4-7"><title>Cell cycle analysis</title><p>Cells were synchronized using double thymidine block as described previously (<xref ref-type="bibr" rid="bib13">Dasgupta et al., 2016</xref>). Samples were harvested, fixed, and stained with 10 Î¼g/mL propidium iodide (PI) and 250 Î¼g/mL RNase A, 37Â°C for 30 min. Cells were then analyzed using a Beckman Coulter Gallios Flow Cytometer.</p></sec><sec id="s4-8"><title>Immunofluorescence and imaging</title><p>Cells stained for FBL, gH2AX, and TP53 were imaged using an Opera Phenix high content screening system, with 63x water objectives in confocal mode. Spot enumeration and signal intensities were analyzed using Harmony software (PerkinElmer). CMK orÂ MCF10AÂ cells were fixed with 4% (v/v) paraformaldehyde in PBS for 10 min, then permeablized with 0.1% Triton in PBS. CMK cells were spun onto slides using SHANDON cytospin prior to fixation. Cells were blocked with 2% (w/v) bovine serum albumin in PBS, then incubated with primary antibody overnight at 4Â°C. The next day, cells were washed with PBS and incubated with secondary antibody andÂ Hoechst 33342Â (1Â Âµg/mL) at room temperature for 1 hr. Cells were then washed and mounted on slides using ProLong Gold Anti-fade (Life Technologies) or DAKO mounting medium. Imaging was done using a Nikon C2 confocal microscope with NIS ElementsÂ softwareÂ and images were processed and quantified using Image J or FIJI software.</p></sec><sec id="s4-9"><title>High-throughput compound screen</title><p>3009 compounds from an FDA-approved, kinase inhibitors and epigenetic libraries (Compounds Australia, Griffith University, Australia) were screened against MCF10A parental and MCF10A cohesin-deficient clones. Compounds are stored by Compounds Australia under robust environmental conditions and supplied in assay ready plate format. MCF10A parental cells and cohesin-deficient derivatives were screened as single biological replicates with two technical replicates for each drug concentration. MCF10A parental cells were seeded at 600 cells/well, <italic>RAD21+</italic>/-Â at 800 cells/well, <italic>SMC3+/</italic>-Â at 1200 cells/well and <italic>STAG2-/</italic>-Â at 700 cells/well, into 384-well CellCarrier-384 Ultra microplates (PerkinElmer) with EL406 microplate washer dispenser (BioTek). 24 hr later, growth media was aspirated from the plates and 35 ÂµL of fresh MCF10A complete growth media was added into each well using BioTek EL406TM Microplate washer dispenser. 5 ÂµL of 8x concentrated compound solution (diluted in MCF10A complete growth media) was added into each well with a JANUS automated liquid handling system (PerkinElmer). At the time of drug treatment, one untreated plate was retained to determine the cell number at tÂ =Â 0. For the rest of the assay plate, compounds were added in 40 ÂµL of complete medium per well using an Echo 550 Liquid Handler (Labcyte). Positive (Campthothecin, 40 nM) and negative controls (DMSO 0.1%) were added to each assay plate for quality control. Duplicated control plates of each cell line were also prepared for cell count quantification prior to the addition of drugs, to be used in the growth rate inhibition (GR) metrics. After 48 hr, control and treated cells in were fixed and stained simultaneously using 4% PFA/0.5Â Âµg/mL DAPI/0.1% Triton X-100 solution. Cells were imaged using an Opera Phenix high content screening system and analyzed using Columbus software (PerkinElmer) using 20x water objectives. To determine compound activity, dose-response curves for each compound was plotted and using an R package, GRmetrics (<xref ref-type="bibr" rid="bib9">Clark et al., 2017</xref>). Synthetic lethal candidate compounds were selected and ranked based on the differential area over curve (AOC) metrics (<xref ref-type="bibr" rid="bib22">Hafner et al., 2016</xref>) derived from dose-response curves of MCF10A parental and cohesin-deficient cell lines. Compounds that causedÂ â¥30% growth inhibition (AOCÂ â¥0.15) in cohesin-deficient clones compared with parental MCF10A cells were selected as hits. A secondary screen was performed with 85 candidate hits identified from primary screen (two technical replicates per clone per concentration). The secondary screen was added to independently validate primary screen data. Activity of the selected compounds was tested in eleven concentrations (0.5 nM to 10 ÂµM). Secondary screen hit compounds were selected based on the same threshold used in primary screen.</p></sec><sec id="s4-10"><title>Cell viability assays to validate compounds identified from the screen</title><p>Individual compounds were purchased from Sigma-Aldrich, Selleck Chem or MedChemExpress and dissolved in DMSO at recommended concentrations. MCF10A parental cells were seeded in 96-well plates at 3000 cells/well, <italic>RAD21+/</italic>-Â at 4500 cells/well, <italic>SMC3+/</italic>-Â at 5000 cells/well and <italic>STAG2-/</italic>-Â at 3500 cells/well. Cells were incubated for 24 hr then treated with compounds for 48 hr. DAPI-stained cells were counted using a Lionheart FX automated microscope (BioTek). K562 parental and <italic>STAG2</italic>-/-Â cells were seeded at 2000 cells per well in 96 well plates, incubated with the compound for 48 hr after which viability was measured using 3-(4,5-dimethylthiazol-2-yl)â2,5-diphenyltetrazolium bromide or MTT.</p></sec><sec id="s4-11"><title>RNA-sequencing and analyses</title><p>Total RNA was extracted using NucleoSpin RNA kit (Machery-Nagel). MCF10A libraries from three biological replicates of each cell type were prepared using NEBNext Ultra RNA Library Prep Kit (Illumina) and sequenced on HiSeq X by Annoroad Gene Technology Ltd. (Beijing, China), contracted through Custom Science (NZ). CMK lines were treated with 200 ng/mL of recombinant human WNT3A (R and D systems) for 4 hr. Libraries were prepared from baseline (non-treated) and WNT3A treated CMK cell lines using Illumina TruSeq stranded mRNA library and sequenced on the HiSeq 2500 V4 at the Otago Genomics Facility (Dunedin, New Zealand). RNA-sequencing reads were first trimmed for sequencing adapters and low quality (qÂ &lt;Â 20). Cleaned reads were then aligned to the human genome GRCh37 (hg19) using HISAT2 version 2.0.5 with gene annotation from Ensembl version 75. Read counts were retrieved by exon and summarized by gene using featureCount (<xref ref-type="bibr" rid="bib31">Liao et al., 2014</xref>) version v1.5.3. Differentially expressed genes in the <italic>STAG2-/</italic>-Â mutants versus wild type were identified using DESeq2 (<xref ref-type="bibr" rid="bib34">Love et al., 2014</xref>). P-values were adjusted for multi-test following Benjamini-Hochberg methodology. Pathways analyses were performed using Molecular Signature Databases ReactomePA (<xref ref-type="bibr" rid="bib84">Yu and He, 2016</xref>) and clusterProfiler (<xref ref-type="bibr" rid="bib83">Yu et al., 2012</xref>) on differentially expressed genes.</p></sec><sec id="s4-12"><title>Zebrafish methods and imaging</title><p>Wild type (WIK), TCF reporter line <italic>Tg(7xTCF-Xla.Siam:nslmCherry)</italic><sup>ia5</sup> (<xref ref-type="bibr" rid="bib44">Moro et al., 2012</xref>), <italic>stag2b</italic><sup>nz207</sup> (<xref ref-type="bibr" rid="bib29">Ketharnathan et al., 2020</xref>) and <italic>rad21</italic><sup>nz171</sup> (<xref ref-type="bibr" rid="bib26">Horsfield et al., 2007</xref>) mutant fish lines were maintained according to established husbandry methods (<xref ref-type="bibr" rid="bib78">Westerfield, 1995</xref>). We crossed heterozygous <italic>rad21</italic><sup>nz171</sup> or homozygous <italic>stag2b</italic><sup>nz207</sup> mutants to the TCF reporter line then crossed these fish (<italic>rad21</italic><sup>nz171</sup>/+;TCF/+) to <italic>rad21</italic><sup>nz171</sup>/+, or (<italic>stag2b</italic><sup>nz207</sup>/+;TCF/+) to <italic>stag2b</italic><sup>nz207</sup>/+. Progeny carrying the TCF reporter were incubated with 0.15 M lithium chloride (LiCl) from 4 hpf for 16 hr. LiCl salt was directly dissolved in embryo water and added to embryos in six well plates. 50 embryos were used per treatment group. At 20 hpf, embryos were washed, anesthetized with MS-222 (200 mg/L) and mounted in low melting agarose (0.6%) or 3% methyl cellulose for imaging. Z-stacks were acquired using a Nikon C2 confocal microscope. Embryos were genotyped post-imaging.</p></sec><sec id="s4-13"><title>Statistical analyses</title><p>All statistical analyses were carried out using R Studio or Prism version eight software (GraphPad).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors are grateful to the ANU Centre for Therapeutic Discovery at the John Curtin School of Medical Research at Australian National University for assistance with screening. We acknowledge Compounds Australia (<ext-link ext-link-type="uri" xlink:href="https://www.compoundsaustralia.com">https://www.compoundsaustralia.com</ext-link>) for their provision of specialized compound management and logistics research services to the project.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Visualization</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Supervision, Funding acquisition</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Supervision, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Supervision, Methodology</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Work with zebrafish was approved by the University of Otago (Dunedin) Animal Ethics Committee (AUP19/17) and conducted using approved institutional animal care standard operating procedures.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of sgRNA sequences and PCR primers.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-61405-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>TCGA analysis of STAG2 mutant vs wild type cancers.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-61405-supp2-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-61405-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All RNA sequencing data has been deposited at the GEO database under accession codes GSE154086. All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1-5 and Table 1.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>CV</given-names></name><name><surname>Antony</surname><given-names>J</given-names></name><name><surname>Gimenez</surname><given-names>G</given-names></name><name><surname>Horsfield</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Expression profiling in cohesin mutant MCF10A epithelial and CMK leukaemia cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE154086">GSE154086</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antony</surname> <given-names>J</given-names></name><name><surname>Dasgupta</surname> <given-names>T</given-names></name><name><surname>Rhodes</surname> <given-names>JM</given-names></name><name><surname>McEwan</surname> <given-names>MV</given-names></name><name><surname>Print</surname> <given-names>CG</given-names></name><name><surname>OâSullivan</surname> <given-names>JM</given-names></name><name><surname>Horsfield</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cohesin modulates transcription of estrogen-responsive genes</article-title><source>Biochimica Et Biophysica Acta (BBA) - Gene Regulatory Mechanisms</source><volume>1849</volume><fpage>257</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.12.011</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antony</surname> <given-names>J</given-names></name><name><surname>Gimenez</surname> <given-names>G</given-names></name><name><surname>Taylor</surname> <given-names>T</given-names></name><name><surname>Khatoon</surname> <given-names>U</given-names></name><name><surname>Day</surname> <given-names>R</given-names></name><name><surname>Morison</surname> <given-names>IM</given-names></name><name><surname>Horsfield</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BET inhibition prevents aberrant RUNX1 and ERG transcription in STAG2 mutant leukaemia cells</article-title><source>Journal of Molecular Cell Biology</source><volume>12</volume><fpage>397</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjz114</pub-id><pub-id pub-id-type="pmid">31897485</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname> <given-names>JM</given-names></name><name><surname>Rank</surname> <given-names>KB</given-names></name><name><surname>Zeng</surname> <given-names>Y</given-names></name><name><surname>Capen</surname> <given-names>A</given-names></name><name><surname>Yadav</surname> <given-names>V</given-names></name><name><surname>Manro</surname> <given-names>JR</given-names></name><name><surname>Engler</surname> <given-names>TA</given-names></name><name><surname>Chedid</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Activating the wnt/Î²-Catenin pathway for the treatment of melanoma--application of LY2090314, a novel selective inhibitor of glycogen synthase Kinase-3</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0125028</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0125028</pub-id><pub-id pub-id-type="pmid">25915038</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avagliano</surname> <given-names>L</given-names></name><name><surname>Grazioli</surname> <given-names>P</given-names></name><name><surname>Mariani</surname> <given-names>M</given-names></name><name><surname>Bulfamante</surname> <given-names>GP</given-names></name><name><surname>Selicorni</surname> <given-names>A</given-names></name><name><surname>Massa</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Integrating molecular and structural findings: wnt as a possible actor in shaping cognitive impairment in cornelia de lange syndrome</article-title><source>Orphanet Journal of Rare Diseases</source><volume>12</volume><elocation-id>174</elocation-id><pub-id pub-id-type="doi">10.1186/s13023-017-0723-0</pub-id><pub-id pub-id-type="pmid">29162129</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname> <given-names>ML</given-names></name><name><surname>O'Neil</surname> <given-names>NJ</given-names></name><name><surname>van Pel</surname> <given-names>DM</given-names></name><name><surname>Solomon</surname> <given-names>DA</given-names></name><name><surname>Waldman</surname> <given-names>T</given-names></name><name><surname>Hieter</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition</article-title><source>Molecular Cancer Therapeutics</source><volume>13</volume><fpage>724</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0749</pub-id><pub-id pub-id-type="pmid">24356817</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beghini</surname> <given-names>A</given-names></name><name><surname>Corlazzoli</surname> <given-names>F</given-names></name><name><surname>Del Giacco</surname> <given-names>L</given-names></name><name><surname>Re</surname> <given-names>M</given-names></name><name><surname>Lazzaroni</surname> <given-names>F</given-names></name><name><surname>Brioschi</surname> <given-names>M</given-names></name><name><surname>Valentini</surname> <given-names>G</given-names></name><name><surname>Ferrazzi</surname> <given-names>F</given-names></name><name><surname>Ghilardi</surname> <given-names>A</given-names></name><name><surname>Righi</surname> <given-names>M</given-names></name><name><surname>Turrini</surname> <given-names>M</given-names></name><name><surname>Mignardi</surname> <given-names>M</given-names></name><name><surname>Cesana</surname> <given-names>C</given-names></name><name><surname>Bronte</surname> <given-names>V</given-names></name><name><surname>Nilsson</surname> <given-names>M</given-names></name><name><surname>Morra</surname> <given-names>E</given-names></name><name><surname>Cairoli</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells</article-title><source>Neoplasia</source><volume>14</volume><fpage>1236</fpage><lpage>IN45</lpage><pub-id pub-id-type="doi">10.1593/neo.121480</pub-id><pub-id pub-id-type="pmid">23308055</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedetti</surname> <given-names>L</given-names></name><name><surname>Cereda</surname> <given-names>M</given-names></name><name><surname>Monteverde</surname> <given-names>L</given-names></name><name><surname>Desai</surname> <given-names>N</given-names></name><name><surname>Ciccarelli</surname> <given-names>FD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Synthetic lethal interaction between the tumour suppressor <italic>STAG2</italic> and its paralog <italic>STAG1</italic></article-title><source>Oncotarget</source><volume>8</volume><fpage>37619</fpage><lpage>37632</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16838</pub-id><pub-id pub-id-type="pmid">28430577</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>KK</given-names></name><name><surname>Lu</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Harris</surname> <given-names>B</given-names></name><name><surname>Slaughter</surname> <given-names>B</given-names></name><name><surname>Unruh</surname> <given-names>J</given-names></name><name><surname>Garrett</surname> <given-names>A</given-names></name><name><surname>McDowell</surname> <given-names>W</given-names></name><name><surname>Box</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Peak</surname> <given-names>A</given-names></name><name><surname>Ramachandran</surname> <given-names>S</given-names></name><name><surname>Seidel</surname> <given-names>C</given-names></name><name><surname>Gerton</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cohesin proteins promote ribosomal RNA production and protein translation in yeast and human cells</article-title><source>PLOS Genetics</source><volume>8</volume><elocation-id>e1002749</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002749</pub-id><pub-id pub-id-type="pmid">22719263</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname> <given-names>NA</given-names></name><name><surname>Hafner</surname> <given-names>M</given-names></name><name><surname>Kouril</surname> <given-names>M</given-names></name><name><surname>Williams</surname> <given-names>EH</given-names></name><name><surname>Muhlich</surname> <given-names>JL</given-names></name><name><surname>Pilarczyk</surname> <given-names>M</given-names></name><name><surname>Niepel</surname> <given-names>M</given-names></name><name><surname>Sorger</surname> <given-names>PK</given-names></name><name><surname>Medvedovic</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GRcalculator: an online tool for calculating and mining dose-response data</article-title><source>BMC Cancer</source><volume>17</volume><elocation-id>698</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-017-3689-3</pub-id><pub-id pub-id-type="pmid">29065900</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname> <given-names>H</given-names></name><name><surname>Loh</surname> <given-names>KM</given-names></name><name><surname>Nusse</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Stem cell signaling an integral program for tissue renewal and regeneration: wnt signaling and stem cell control</article-title><source>Science</source><volume>346</volume><elocation-id>1248012</elocation-id><pub-id pub-id-type="doi">10.1126/science.1248012</pub-id><pub-id pub-id-type="pmid">25278615</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cucco</surname> <given-names>F</given-names></name><name><surname>Servadio</surname> <given-names>A</given-names></name><name><surname>Gatti</surname> <given-names>V</given-names></name><name><surname>Bianchi</surname> <given-names>P</given-names></name><name><surname>Mannini</surname> <given-names>L</given-names></name><name><surname>Prodosmo</surname> <given-names>A</given-names></name><name><surname>De Vitis</surname> <given-names>E</given-names></name><name><surname>Basso</surname> <given-names>G</given-names></name><name><surname>Friuli</surname> <given-names>A</given-names></name><name><surname>Laghi</surname> <given-names>L</given-names></name><name><surname>Soddu</surname> <given-names>S</given-names></name><name><surname>Fontanini</surname> <given-names>G</given-names></name><name><surname>Musio</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mutant cohesin drives chromosomal instability in early colorectal adenomas</article-title><source>Human Molecular Genetics</source><volume>23</volume><fpage>6773</fpage><lpage>6778</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu394</pub-id><pub-id pub-id-type="pmid">25080505</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cukrov</surname> <given-names>D</given-names></name><name><surname>Newman</surname> <given-names>TAC</given-names></name><name><surname>Leask</surname> <given-names>M</given-names></name><name><surname>Leeke</surname> <given-names>B</given-names></name><name><surname>Sarogni</surname> <given-names>P</given-names></name><name><surname>Patimo</surname> <given-names>A</given-names></name><name><surname>Kline</surname> <given-names>AD</given-names></name><name><surname>Krantz</surname> <given-names>ID</given-names></name><name><surname>Horsfield</surname> <given-names>JA</given-names></name><name><surname>Musio</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antioxidant treatment ameliorates phenotypic features of SMC1A-mutated cornelia de lange syndrome in vitro and in vivo</article-title><source>Human Molecular Genetics</source><volume>27</volume><fpage>3002</fpage><lpage>3011</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy203</pub-id><pub-id pub-id-type="pmid">29860495</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname> <given-names>T</given-names></name><name><surname>Antony</surname> <given-names>J</given-names></name><name><surname>Braithwaite</surname> <given-names>AW</given-names></name><name><surname>Horsfield</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>HDAC8 inhibition blocks SMC3 deacetylation and delays cell cycle progression without affecting Cohesin-dependent transcription in MCF7 Cancer cells</article-title><source>Journal of Biological Chemistry</source><volume>291</volume><fpage>12761</fpage><lpage>12770</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.704627</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Koninck</surname> <given-names>M</given-names></name><name><surname>Losada</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cohesin mutations in cancer</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>6</volume><elocation-id>a026476</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a026476</pub-id><pub-id pub-id-type="pmid">27742736</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorsett</surname> <given-names>D</given-names></name><name><surname>StrÃ¶m</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The ancient and evolving roles of cohesin in gene expression and DNA repair</article-title><source>Current Biology</source><volume>22</volume><fpage>R240</fpage><lpage>R250</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2012.02.046</pub-id><pub-id pub-id-type="pmid">22497943</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emmrich</surname> <given-names>S</given-names></name><name><surname>Rasche</surname> <given-names>M</given-names></name><name><surname>SchÃ¶ning</surname> <given-names>J</given-names></name><name><surname>Reimer</surname> <given-names>C</given-names></name><name><surname>Keihani</surname> <given-names>S</given-names></name><name><surname>Maroz</surname> <given-names>A</given-names></name><name><surname>Xie</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Schambach</surname> <given-names>A</given-names></name><name><surname>Reinhardt</surname> <given-names>D</given-names></name><name><surname>Klusmann</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between tgfÎ² and wnt signaling</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>858</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1101/gad.233791.113</pub-id><pub-id pub-id-type="pmid">24736844</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erbilgin</surname> <given-names>Y</given-names></name><name><surname>Ng</surname> <given-names>OH</given-names></name><name><surname>Mavi</surname> <given-names>N</given-names></name><name><surname>Ozbek</surname> <given-names>U</given-names></name><name><surname>Sayitoglu</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genetic alterations in members of the wnt pathway in acute leukemia</article-title><source>Leukemia &amp; Lymphoma</source><volume>53</volume><fpage>508</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.3109/10428194.2011.613133</pub-id><pub-id pub-id-type="pmid">21902576</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>EstarÃ¡s</surname> <given-names>C</given-names></name><name><surname>Benner</surname> <given-names>C</given-names></name><name><surname>Jones</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SMADs and YAP compete to control elongation of Î²-catenin:lef-1-recruited RNAPII during hESC differentiation</article-title><source>Molecular Cell</source><volume>58</volume><fpage>780</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.04.001</pub-id><pub-id pub-id-type="pmid">25936800</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galeev</surname> <given-names>R</given-names></name><name><surname>Baudet</surname> <given-names>A</given-names></name><name><surname>Kumar</surname> <given-names>P</given-names></name><name><surname>Rundberg Nilsson</surname> <given-names>A</given-names></name><name><surname>Nilsson</surname> <given-names>B</given-names></name><name><surname>Soneji</surname> <given-names>S</given-names></name><name><surname>TÃ¶rngren</surname> <given-names>T</given-names></name><name><surname>Borg</surname> <given-names>Ã</given-names></name><name><surname>Kvist</surname> <given-names>A</given-names></name><name><surname>Larsson</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genome-wide RNAi screen identifies cohesin genes as modifiers of renewal and differentiation in human HSCs</article-title><source>Cell Reports</source><volume>14</volume><fpage>2988</fpage><lpage>3000</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.02.082</pub-id><pub-id pub-id-type="pmid">26997282</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghiselli</surname> <given-names>G</given-names></name><name><surname>Coffee</surname> <given-names>N</given-names></name><name><surname>Munnery</surname> <given-names>CE</given-names></name><name><surname>Koratkar</surname> <given-names>R</given-names></name><name><surname>Siracusa</surname> <given-names>LD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The cohesin SMC3 is a target the for Î²-Catenin/TCF4 transactivation pathway</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>20259</fpage><lpage>20267</lpage><pub-id pub-id-type="doi">10.1074/jbc.M209511200</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname> <given-names>RL</given-names></name><name><surname>Heath</surname> <given-names>AP</given-names></name><name><surname>Ferretti</surname> <given-names>V</given-names></name><name><surname>Varmus</surname> <given-names>HE</given-names></name><name><surname>Lowy</surname> <given-names>DR</given-names></name><name><surname>Kibbe</surname> <given-names>WA</given-names></name><name><surname>Staudt</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Toward a shared vision for Cancer genomic data</article-title><source>New England Journal of Medicine</source><volume>375</volume><fpage>1109</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1607591</pub-id><pub-id pub-id-type="pmid">27653561</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafner</surname> <given-names>M</given-names></name><name><surname>Niepel</surname> <given-names>M</given-names></name><name><surname>Chung</surname> <given-names>M</given-names></name><name><surname>Sorger</surname> <given-names>PK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Growth rate inhibition metrics correct for confounders in measuring sensitivity to Cancer drugs</article-title><source>Nature Methods</source><volume>13</volume><fpage>521</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3853</pub-id><pub-id pub-id-type="pmid">27135972</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CTCF as a boundary factor for cohesin-mediated loop extrusion: evidence for a multi-step mechanism</article-title><source>Nucleus</source><volume>11</volume><fpage>132</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1080/19491034.2020.1782024</pub-id><pub-id pub-id-type="pmid">32631111</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname> <given-names>B</given-names></name><name><surname>Bose</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>KK</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Lu</surname> <given-names>S</given-names></name><name><surname>Ross</surname> <given-names>RT</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>French</surname> <given-names>SL</given-names></name><name><surname>Beyer</surname> <given-names>AL</given-names></name><name><surname>Slaughter</surname> <given-names>BD</given-names></name><name><surname>Unruh</surname> <given-names>JR</given-names></name><name><surname>Gerton</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cohesion promotes nucleolar structure and function</article-title><source>Molecular Biology of the Cell</source><volume>25</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1091/mbc.e13-07-0377</pub-id><pub-id pub-id-type="pmid">24307683</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname> <given-names>VK</given-names></name><name><surname>Kim</surname> <given-names>JS</given-names></name><name><surname>Waldman</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cohesin mutations in human Cancer</article-title><source>Biochimica et Biophysica Acta</source><volume>1866</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2016.05.002</pub-id><pub-id pub-id-type="pmid">27207471</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horsfield</surname> <given-names>JA</given-names></name><name><surname>Anagnostou</surname> <given-names>SH</given-names></name><name><surname>Hu</surname> <given-names>JK-H</given-names></name><name><surname>Cho</surname> <given-names>KHY</given-names></name><name><surname>Geisler</surname> <given-names>R</given-names></name><name><surname>Lieschke</surname> <given-names>G</given-names></name><name><surname>Crosier</surname> <given-names>KE</given-names></name><name><surname>Crosier</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cohesin-dependent regulation of runx genes</article-title><source>Development</source><volume>134</volume><fpage>2639</fpage><lpage>2649</lpage><pub-id pub-id-type="doi">10.1242/dev.002485</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horsfield</surname> <given-names>JA</given-names></name><name><surname>Print</surname> <given-names>CG</given-names></name><name><surname>MÃ¶nnich</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Diverse developmental disorders from the one ring: distinct molecular pathways underlie the cohesinopathies</article-title><source>Frontiers in Genetics</source><volume>3</volume><elocation-id>171</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2012.00171</pub-id><pub-id pub-id-type="pmid">22988450</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>Y-A</given-names></name><name><surname>Pietras</surname> <given-names>EM</given-names></name><name><surname>PasseguÃ©</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Deregulated notch and wnt signaling activates early-stage myeloid regeneration pathways in leukemia</article-title><source>Journal of Experimental Medicine</source><volume>217</volume><elocation-id>20190787</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20190787</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ketharnathan</surname> <given-names>S</given-names></name><name><surname>Labudina</surname> <given-names>A</given-names></name><name><surname>Horsfield</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cohesin components Stag1 and Stag2 differentially influence haematopoietic mesoderm development in zebrafish embryos</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>8</volume><elocation-id>617545</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2020.617545</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kon</surname> <given-names>A</given-names></name><name><surname>Shih</surname> <given-names>LY</given-names></name><name><surname>Minamino</surname> <given-names>M</given-names></name><name><surname>Sanada</surname> <given-names>M</given-names></name><name><surname>Shiraishi</surname> <given-names>Y</given-names></name><name><surname>Nagata</surname> <given-names>Y</given-names></name><name><surname>Yoshida</surname> <given-names>K</given-names></name><name><surname>Okuno</surname> <given-names>Y</given-names></name><name><surname>Bando</surname> <given-names>M</given-names></name><name><surname>Nakato</surname> <given-names>R</given-names></name><name><surname>Ishikawa</surname> <given-names>S</given-names></name><name><surname>Sato-Otsubo</surname> <given-names>A</given-names></name><name><surname>Nagae</surname> <given-names>G</given-names></name><name><surname>Nishimoto</surname> <given-names>A</given-names></name><name><surname>Haferlach</surname> <given-names>C</given-names></name><name><surname>Nowak</surname> <given-names>D</given-names></name><name><surname>Sato</surname> <given-names>Y</given-names></name><name><surname>Alpermann</surname> <given-names>T</given-names></name><name><surname>Nagasaki</surname> <given-names>M</given-names></name><name><surname>Shimamura</surname> <given-names>T</given-names></name><name><surname>Tanaka</surname> <given-names>H</given-names></name><name><surname>Chiba</surname> <given-names>K</given-names></name><name><surname>Yamamoto</surname> <given-names>R</given-names></name><name><surname>Yamaguchi</surname> <given-names>T</given-names></name><name><surname>Otsu</surname> <given-names>M</given-names></name><name><surname>Obara</surname> <given-names>N</given-names></name><name><surname>Sakata-Yanagimoto</surname> <given-names>M</given-names></name><name><surname>Nakamaki</surname> <given-names>T</given-names></name><name><surname>Ishiyama</surname> <given-names>K</given-names></name><name><surname>Nolte</surname> <given-names>F</given-names></name><name><surname>Hofmann</surname> <given-names>WK</given-names></name><name><surname>Miyawaki</surname> <given-names>S</given-names></name><name><surname>Chiba</surname> <given-names>S</given-names></name><name><surname>Mori</surname> <given-names>H</given-names></name><name><surname>Nakauchi</surname> <given-names>H</given-names></name><name><surname>Koeffler</surname> <given-names>HP</given-names></name><name><surname>Aburatani</surname> <given-names>H</given-names></name><name><surname>Haferlach</surname> <given-names>T</given-names></name><name><surname>Shirahige</surname> <given-names>K</given-names></name><name><surname>Miyano</surname> <given-names>S</given-names></name><name><surname>Ogawa</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1232</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1038/ng.2731</pub-id><pub-id pub-id-type="pmid">23955599</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Van der Jeught</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Fang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Radovich</surname> <given-names>M</given-names></name><name><surname>Schneider</surname> <given-names>BP</given-names></name><name><surname>He</surname> <given-names>X</given-names></name><name><surname>Huang</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Wan</surname> <given-names>J</given-names></name><name><surname>Ji</surname> <given-names>G</given-names></name><name><surname>Lu</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in Cancer</article-title><source>Journal of Clinical Investigation</source><volume>128</volume><fpage>2951</fpage><lpage>2965</lpage><pub-id pub-id-type="doi">10.1172/JCI98727</pub-id><pub-id pub-id-type="pmid">29649003</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname> <given-names>CY</given-names></name><name><surname>Nusse</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The wnt signaling pathway in development and disease</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>20</volume><fpage>781</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.20.010403.113126</pub-id><pub-id pub-id-type="pmid">15473860</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname> <given-names>BT</given-names></name><name><surname>Tamai</surname> <given-names>K</given-names></name><name><surname>He</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Wnt/beta-catenin signaling: components, mechanisms, and diseases</article-title><source>Developmental Cell</source><volume>17</volume><fpage>9</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2009.06.016</pub-id><pub-id pub-id-type="pmid">19619488</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matto</surname> <given-names>N</given-names></name><name><surname>Gaymes</surname> <given-names>TJ</given-names></name><name><surname>Kulasekararaj</surname> <given-names>AG</given-names></name><name><surname>Mian</surname> <given-names>SA</given-names></name><name><surname>Mufti</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutations in cohesin complex as potential targets for therapeutic intervention by PARP (Poly ADP ribose polymerase) Inhibitors in myelodysplastic syndrome</article-title><source>Blood</source><volume>126</volume><elocation-id>1221</elocation-id><pub-id pub-id-type="doi">10.1182/blood.V126.23.1221.1221</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayerova</surname> <given-names>N</given-names></name><name><surname>Cipak</surname> <given-names>L</given-names></name><name><surname>Gregan</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cohesin biology: from passive rings to molecular motors</article-title><source>Trends in Genetics</source><volume>36</volume><fpage>387</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2020.03.001</pub-id><pub-id pub-id-type="pmid">32396831</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazumdar</surname> <given-names>C</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Xavy</surname> <given-names>S</given-names></name><name><surname>Zhao</surname> <given-names>F</given-names></name><name><surname>Reinisch</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Corces</surname> <given-names>MR</given-names></name><name><surname>Flynn</surname> <given-names>RA</given-names></name><name><surname>Buenrostro</surname> <given-names>JD</given-names></name><name><surname>Chan</surname> <given-names>SM</given-names></name><name><surname>Thomas</surname> <given-names>D</given-names></name><name><surname>Koenig</surname> <given-names>JL</given-names></name><name><surname>Hong</surname> <given-names>WJ</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>Majeti</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Leukemia-Associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation</article-title><source>Cell Stem Cell</source><volume>17</volume><fpage>675</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.09.017</pub-id><pub-id pub-id-type="pmid">26607380</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazumdar</surname> <given-names>C</given-names></name><name><surname>Majeti</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The role of mutations in the cohesin complex in acute myeloid leukemia</article-title><source>International Journal of Hematology</source><volume>105</volume><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s12185-016-2119-7</pub-id><pub-id pub-id-type="pmid">27796738</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzola</surname> <given-names>M</given-names></name><name><surname>Deflorian</surname> <given-names>G</given-names></name><name><surname>Pezzotta</surname> <given-names>A</given-names></name><name><surname>Ferrari</surname> <given-names>L</given-names></name><name><surname>Fazio</surname> <given-names>G</given-names></name><name><surname>Bresciani</surname> <given-names>E</given-names></name><name><surname>Saitta</surname> <given-names>C</given-names></name><name><surname>Ferrari</surname> <given-names>L</given-names></name><name><surname>Fumagalli</surname> <given-names>M</given-names></name><name><surname>Parma</surname> <given-names>M</given-names></name><name><surname>Marasca</surname> <given-names>F</given-names></name><name><surname>Bodega</surname> <given-names>B</given-names></name><name><surname>Riva</surname> <given-names>P</given-names></name><name><surname>Cotelli</surname> <given-names>F</given-names></name><name><surname>Biondi</surname> <given-names>A</given-names></name><name><surname>Marozzi</surname> <given-names>A</given-names></name><name><surname>Cazzaniga</surname> <given-names>G</given-names></name><name><surname>Pistocchi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>NIPBL</italic>: a new player in myeloid cell differentiation</article-title><source>Haematologica</source><volume>104</volume><fpage>1332</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.3324/haematol.2018.200899</pub-id><pub-id pub-id-type="pmid">30630974</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLellan</surname> <given-names>JL</given-names></name><name><surname>O'Neil</surname> <given-names>NJ</given-names></name><name><surname>Barrett</surname> <given-names>I</given-names></name><name><surname>Ferree</surname> <given-names>E</given-names></name><name><surname>van Pel</surname> <given-names>DM</given-names></name><name><surname>Ushey</surname> <given-names>K</given-names></name><name><surname>Sipahimalani</surname> <given-names>P</given-names></name><name><surname>Bryan</surname> <given-names>J</given-names></name><name><surname>Rose</surname> <given-names>AM</given-names></name><name><surname>Hieter</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Synthetic lethality of cohesins with PARPs and replication fork mediators</article-title><source>PLOS Genetics</source><volume>8</volume><elocation-id>e1002574</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002574</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname> <given-names>JA</given-names></name><name><surname>Herrera</surname> <given-names>PS</given-names></name><name><surname>Kaur</surname> <given-names>M</given-names></name><name><surname>Leo</surname> <given-names>L</given-names></name><name><surname>McEldrew</surname> <given-names>D</given-names></name><name><surname>Tintos-Hernandez</surname> <given-names>JA</given-names></name><name><surname>Rajagopalan</surname> <given-names>R</given-names></name><name><surname>Gagne</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Ortiz-Gonzalez</surname> <given-names>XR</given-names></name><name><surname>Krantz</surname> <given-names>ID</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>NIPBL<sup>+/-</sup>Haploinsufficiency reveals a constellation of transcriptome disruptions in the pluripotent and cardiac states</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>1056</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-19173-9</pub-id><pub-id pub-id-type="pmid">29348408</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondal</surname> <given-names>G</given-names></name><name><surname>Stevers</surname> <given-names>M</given-names></name><name><surname>Goode</surname> <given-names>B</given-names></name><name><surname>Ashworth</surname> <given-names>A</given-names></name><name><surname>Solomon</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1686</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09659-z</pub-id><pub-id pub-id-type="pmid">30975996</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moro</surname> <given-names>E</given-names></name><name><surname>Ozhan-Kizil</surname> <given-names>G</given-names></name><name><surname>Mongera</surname> <given-names>A</given-names></name><name><surname>Beis</surname> <given-names>D</given-names></name><name><surname>Wierzbicki</surname> <given-names>C</given-names></name><name><surname>Young</surname> <given-names>RM</given-names></name><name><surname>Bournele</surname> <given-names>D</given-names></name><name><surname>Domenichini</surname> <given-names>A</given-names></name><name><surname>Valdivia</surname> <given-names>LE</given-names></name><name><surname>Lum</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Amatruda</surname> <given-names>JF</given-names></name><name><surname>Tiso</surname> <given-names>N</given-names></name><name><surname>Weidinger</surname> <given-names>G</given-names></name><name><surname>Argenton</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>In vivo wnt signaling tracing through a transgenic biosensor fish reveals novel activity domains</article-title><source>Developmental Biology</source><volume>366</volume><fpage>327</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2012.03.023</pub-id><pub-id pub-id-type="pmid">22546689</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullenders</surname> <given-names>J</given-names></name><name><surname>Aranda-Orgilles</surname> <given-names>B</given-names></name><name><surname>Lhoumaud</surname> <given-names>P</given-names></name><name><surname>Keller</surname> <given-names>M</given-names></name><name><surname>Pae</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Kayembe</surname> <given-names>C</given-names></name><name><surname>Rocha</surname> <given-names>PP</given-names></name><name><surname>Raviram</surname> <given-names>R</given-names></name><name><surname>Gong</surname> <given-names>Y</given-names></name><name><surname>Premsrirut</surname> <given-names>PK</given-names></name><name><surname>Tsirigos</surname> <given-names>A</given-names></name><name><surname>Bonneau</surname> <given-names>R</given-names></name><name><surname>Skok</surname> <given-names>JA</given-names></name><name><surname>Cimmino</surname> <given-names>L</given-names></name><name><surname>Hoehn</surname> <given-names>D</given-names></name><name><surname>Aifantis</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms</article-title><source>Journal of Experimental Medicine</source><volume>212</volume><fpage>1833</fpage><lpage>1850</lpage><pub-id pub-id-type="doi">10.1084/jem.20151323</pub-id><pub-id pub-id-type="pmid">26438359</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niida</surname> <given-names>A</given-names></name><name><surname>Hiroko</surname> <given-names>T</given-names></name><name><surname>Kasai</surname> <given-names>M</given-names></name><name><surname>Furukawa</surname> <given-names>Y</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Suzuki</surname> <given-names>Y</given-names></name><name><surname>Sugano</surname> <given-names>S</given-names></name><name><surname>Akiyama</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>DKK1, a negative regulator of wnt signaling, is a target of the beta-catenin/TCF pathway</article-title><source>Oncogene</source><volume>23</volume><fpage>8520</fpage><lpage>8526</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207892</pub-id><pub-id pub-id-type="pmid">15378020</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neil</surname> <given-names>NJ</given-names></name><name><surname>van Pel</surname> <given-names>DM</given-names></name><name><surname>Hieter</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Synthetic lethality and Cancer: cohesin and PARP at the replication fork</article-title><source>Trends in Genetics</source><volume>29</volume><fpage>290</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2012.12.004</pub-id><pub-id pub-id-type="pmid">23333522</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oginuma</surname> <given-names>M</given-names></name><name><surname>Moncuquet</surname> <given-names>P</given-names></name><name><surname>Xiong</surname> <given-names>F</given-names></name><name><surname>Karoly</surname> <given-names>E</given-names></name><name><surname>Chal</surname> <given-names>J</given-names></name><name><surname>Guevorkian</surname> <given-names>K</given-names></name><name><surname>PourquiÃ©</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A gradient of glycolytic activity coordinates FGF and wnt signaling during elongation of the body Axis in amniote embryos</article-title><source>Developmental Cell</source><volume>40</volume><fpage>342</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2017.02.001</pub-id><pub-id pub-id-type="pmid">28245921</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oginuma</surname> <given-names>M</given-names></name><name><surname>Harima</surname> <given-names>Y</given-names></name><name><surname>Tarazona</surname> <given-names>OA</given-names></name><name><surname>Diaz-Cuadros</surname> <given-names>M</given-names></name><name><surname>Michaut</surname> <given-names>A</given-names></name><name><surname>Ishitani</surname> <given-names>T</given-names></name><name><surname>Xiong</surname> <given-names>F</given-names></name><name><surname>PourquiÃ©</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Intracellular pH controls WNT downstream of glycolysis in amniote embryos</article-title><source>Nature</source><volume>584</volume><fpage>98</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2428-0</pub-id><pub-id pub-id-type="pmid">32581357</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname> <given-names>H</given-names></name><name><surname>Jin</surname> <given-names>M</given-names></name><name><surname>Ghadiyaram</surname> <given-names>A</given-names></name><name><surname>Kaur</surname> <given-names>P</given-names></name><name><surname>Miller</surname> <given-names>HE</given-names></name><name><surname>Ta</surname> <given-names>HM</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Fan</surname> <given-names>Y</given-names></name><name><surname>Mahn</surname> <given-names>C</given-names></name><name><surname>Gorthi</surname> <given-names>A</given-names></name><name><surname>You</surname> <given-names>C</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name><name><surname>Riehn</surname> <given-names>R</given-names></name><name><surname>Bishop</surname> <given-names>AJR</given-names></name><name><surname>Tao</surname> <given-names>YJ</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cohesin SA1 and SA2 are RNA binding proteins that localize to RNA containing regions on DNA</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>5639</fpage><lpage>5655</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa284</pub-id><pub-id pub-id-type="pmid">32352519</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papaemmanuil</surname> <given-names>E</given-names></name><name><surname>Gerstung</surname> <given-names>M</given-names></name><name><surname>Bullinger</surname> <given-names>L</given-names></name><name><surname>Gaidzik</surname> <given-names>VI</given-names></name><name><surname>Paschka</surname> <given-names>P</given-names></name><name><surname>Roberts</surname> <given-names>ND</given-names></name><name><surname>Potter</surname> <given-names>NE</given-names></name><name><surname>Heuser</surname> <given-names>M</given-names></name><name><surname>Thol</surname> <given-names>F</given-names></name><name><surname>Bolli</surname> <given-names>N</given-names></name><name><surname>Gundem</surname> <given-names>G</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Martincorena</surname> <given-names>I</given-names></name><name><surname>Ganly</surname> <given-names>P</given-names></name><name><surname>Mudie</surname> <given-names>L</given-names></name><name><surname>McLaren</surname> <given-names>S</given-names></name><name><surname>O'Meara</surname> <given-names>S</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Jones</surname> <given-names>DR</given-names></name><name><surname>Teague</surname> <given-names>JW</given-names></name><name><surname>Butler</surname> <given-names>AP</given-names></name><name><surname>Greaves</surname> <given-names>MF</given-names></name><name><surname>Ganser</surname> <given-names>A</given-names></name><name><surname>DÃ¶hner</surname> <given-names>K</given-names></name><name><surname>Schlenk</surname> <given-names>RF</given-names></name><name><surname>DÃ¶hner</surname> <given-names>H</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic classification and prognosis in acute myeloid leukemia</article-title><source>New England Journal of Medicine</source><volume>374</volume><fpage>2209</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1516192</pub-id><pub-id pub-id-type="pmid">27276561</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parks</surname> <given-names>SK</given-names></name><name><surname>Chiche</surname> <given-names>J</given-names></name><name><surname>PouyssÃ©gur</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Disrupting proton dynamics and energy metabolism for Cancer therapy</article-title><source>Nature Reviews Cancer</source><volume>13</volume><fpage>611</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1038/nrc3579</pub-id><pub-id pub-id-type="pmid">23969692</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pistocchi</surname> <given-names>A</given-names></name><name><surname>Fazio</surname> <given-names>G</given-names></name><name><surname>Cereda</surname> <given-names>A</given-names></name><name><surname>Ferrari</surname> <given-names>L</given-names></name><name><surname>Bettini</surname> <given-names>LR</given-names></name><name><surname>Messina</surname> <given-names>G</given-names></name><name><surname>Cotelli</surname> <given-names>F</given-names></name><name><surname>Biondi</surname> <given-names>A</given-names></name><name><surname>Selicorni</surname> <given-names>A</given-names></name><name><surname>Massa</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cornelia De Lange syndrome: nipbl haploinsufficiency downregulates canonical wnt pathway in zebrafish embryos and patients fibroblasts</article-title><source>Cell Death &amp; Disease</source><volume>4</volume><elocation-id>e866</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2013.371</pub-id><pub-id pub-id-type="pmid">24136230</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prossomariti</surname> <given-names>A</given-names></name><name><surname>Piazzi</surname> <given-names>G</given-names></name><name><surname>Alquati</surname> <given-names>C</given-names></name><name><surname>Ricciardiello</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Are wnt/Î²-Catenin and PI3K/AKT/mTORC1 distinct pathways in colorectal Cancer?</article-title><source>Cellular and Molecular Gastroenterology and Hepatology</source><volume>10</volume><fpage>491</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2020.04.007</pub-id><pub-id pub-id-type="pmid">32334125</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wright</surname> <given-names>J</given-names></name><name><surname>Agarwala</surname> <given-names>V</given-names></name><name><surname>Scott</surname> <given-names>DA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome engineering using the CRISPR-Cas9 system</article-title><source>Nature Protocols</source><volume>8</volume><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id><pub-id pub-id-type="pmid">24157548</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rattis</surname> <given-names>FM</given-names></name><name><surname>Voermans</surname> <given-names>C</given-names></name><name><surname>Reya</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Wnt signaling in the stem cell niche</article-title><source>Current Opinion in Hematology</source><volume>11</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1097/01.moh.0000133649.61121.ec</pub-id><pub-id pub-id-type="pmid">15257024</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero-PÃ©rez</surname> <given-names>L</given-names></name><name><surname>Surdez</surname> <given-names>D</given-names></name><name><surname>Brunet</surname> <given-names>E</given-names></name><name><surname>Delattre</surname> <given-names>O</given-names></name><name><surname>GrÃ¼newald</surname> <given-names>TGP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>STAG mutations in cancer</article-title><source>Trends in Cancer</source><volume>5</volume><fpage>506</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2019.07.001</pub-id><pub-id pub-id-type="pmid">31421907</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname> <given-names>MJ</given-names></name><name><surname>Corces</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Organizational principles of 3D genome architecture</article-title><source>Nature Reviews Genetics</source><volume>19</volume><fpage>789</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1038/s41576-018-0060-8</pub-id><pub-id pub-id-type="pmid">30367165</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarogni</surname> <given-names>P</given-names></name><name><surname>Palumbo</surname> <given-names>O</given-names></name><name><surname>Servadio</surname> <given-names>A</given-names></name><name><surname>Astigiano</surname> <given-names>S</given-names></name><name><surname>D'Alessio</surname> <given-names>B</given-names></name><name><surname>Gatti</surname> <given-names>V</given-names></name><name><surname>Cukrov</surname> <given-names>D</given-names></name><name><surname>Baldari</surname> <given-names>S</given-names></name><name><surname>Pallotta</surname> <given-names>MM</given-names></name><name><surname>Aretini</surname> <given-names>P</given-names></name><name><surname>Dell'Orletta</surname> <given-names>F</given-names></name><name><surname>Soddu</surname> <given-names>S</given-names></name><name><surname>Carella</surname> <given-names>M</given-names></name><name><surname>Toietta</surname> <given-names>G</given-names></name><name><surname>Barbieri</surname> <given-names>O</given-names></name><name><surname>Fontanini</surname> <given-names>G</given-names></name><name><surname>Musio</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Overexpression of the cohesin-core subunit SMC1A contributes to colorectal Cancer development</article-title><source>Journal of Experimental &amp; Clinical Cancer Research</source><volume>38</volume><elocation-id>108</elocation-id><pub-id pub-id-type="doi">10.1186/s13046-019-1116-0</pub-id><pub-id pub-id-type="pmid">30823889</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname> <given-names>K</given-names></name><name><surname>Leeke</surname> <given-names>B</given-names></name><name><surname>Meier</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Newman</surname> <given-names>T</given-names></name><name><surname>Burgess</surname> <given-names>S</given-names></name><name><surname>Horsfield</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A neural crest origin for cohesinopathy heart defects</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>7005</fpage><lpage>7016</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv402</pub-id><pub-id pub-id-type="pmid">26420840</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>Z</given-names></name><name><surname>Gao</surname> <given-names>H</given-names></name><name><surname>Bai</surname> <given-names>XC</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-EM structure of the human cohesin-NIPBL-DNA complex</article-title><source>Science</source><volume>368</volume><fpage>1454</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1126/science.abb0981</pub-id><pub-id pub-id-type="pmid">32409525</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shintomi</surname> <given-names>K</given-names></name><name><surname>Hirano</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Releasing cohesin from chromosome arms in early mitosis: opposing actions of Wapl-Pds5 and Sgo1</article-title><source>Genes &amp; Development</source><volume>23</volume><fpage>2224</fpage><lpage>2236</lpage><pub-id pub-id-type="doi">10.1101/gad.1844309</pub-id><pub-id pub-id-type="pmid">19696148</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>SjÃ¶gren</surname> <given-names>C</given-names></name><name><surname>StrÃ¶m</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>S-phase and DNA damage activated establishment of sister chromatid cohesion--importance for DNA repair</article-title><source>Experimental Cell Research</source><volume>316</volume><fpage>1445</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2009.12.018</pub-id><pub-id pub-id-type="pmid">20043905</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tait</surname> <given-names>L</given-names></name><name><surname>Soule</surname> <given-names>HD</given-names></name><name><surname>Russo</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10</article-title><source>Cancer Research</source><volume>50</volume><fpage>6087</fpage><lpage>6094</lpage><pub-id pub-id-type="pmid">1697506</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Telford</surname> <given-names>BJ</given-names></name><name><surname>Chen</surname> <given-names>A</given-names></name><name><surname>Beetham</surname> <given-names>H</given-names></name><name><surname>Frick</surname> <given-names>J</given-names></name><name><surname>Brew</surname> <given-names>TP</given-names></name><name><surname>Gould</surname> <given-names>CM</given-names></name><name><surname>Single</surname> <given-names>A</given-names></name><name><surname>Godwin</surname> <given-names>T</given-names></name><name><surname>Simpson</surname> <given-names>KJ</given-names></name><name><surname>Guilford</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Synthetic lethal screens identify vulnerabilities in GPCR signaling and cytoskeletal organization in E-Cadherin-Deficient cells</article-title><source>Molecular Cancer Therapeutics</source><volume>14</volume><fpage>1213</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-1092</pub-id><pub-id pub-id-type="pmid">25777964</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thol</surname> <given-names>F</given-names></name><name><surname>Bollin</surname> <given-names>R</given-names></name><name><surname>Gehlhaar</surname> <given-names>M</given-names></name><name><surname>Walter</surname> <given-names>C</given-names></name><name><surname>Dugas</surname> <given-names>M</given-names></name><name><surname>Suchanek</surname> <given-names>KJ</given-names></name><name><surname>Kirchner</surname> <given-names>A</given-names></name><name><surname>Huang</surname> <given-names>L</given-names></name><name><surname>Chaturvedi</surname> <given-names>A</given-names></name><name><surname>Wichmann</surname> <given-names>M</given-names></name><name><surname>Wiehlmann</surname> <given-names>L</given-names></name><name><surname>Shahswar</surname> <given-names>R</given-names></name><name><surname>Damm</surname> <given-names>F</given-names></name><name><surname>GÃ¶hring</surname> <given-names>G</given-names></name><name><surname>Schlegelberger</surname> <given-names>B</given-names></name><name><surname>Schlenk</surname> <given-names>R</given-names></name><name><surname>DÃ¶hner</surname> <given-names>K</given-names></name><name><surname>DÃ¶hner</surname> <given-names>H</given-names></name><name><surname>Krauter</surname> <given-names>J</given-names></name><name><surname>Ganser</surname> <given-names>A</given-names></name><name><surname>Heuser</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications</article-title><source>Blood</source><volume>123</volume><fpage>914</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-07-518746</pub-id><pub-id pub-id-type="pmid">24335498</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thota</surname> <given-names>S</given-names></name><name><surname>Viny</surname> <given-names>AD</given-names></name><name><surname>Makishima</surname> <given-names>H</given-names></name><name><surname>Spitzer</surname> <given-names>B</given-names></name><name><surname>Radivoyevitch</surname> <given-names>T</given-names></name><name><surname>Przychodzen</surname> <given-names>B</given-names></name><name><surname>Sekeres</surname> <given-names>MA</given-names></name><name><surname>Levine</surname> <given-names>RL</given-names></name><name><surname>Maciejewski</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic alterations of the cohesin complex genes in myeloid malignancies</article-title><source>Blood</source><volume>124</volume><fpage>1790</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-04-567057</pub-id><pub-id pub-id-type="pmid">25006131</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname> <given-names>CH</given-names></name><name><surname>Hou</surname> <given-names>HA</given-names></name><name><surname>Tang</surname> <given-names>JL</given-names></name><name><surname>Kuo</surname> <given-names>YY</given-names></name><name><surname>Chiu</surname> <given-names>YC</given-names></name><name><surname>Lin</surname> <given-names>CC</given-names></name><name><surname>Liu</surname> <given-names>CY</given-names></name><name><surname>Tseng</surname> <given-names>MH</given-names></name><name><surname>Lin</surname> <given-names>TY</given-names></name><name><surname>Liu</surname> <given-names>MC</given-names></name><name><surname>Liu</surname> <given-names>CW</given-names></name><name><surname>Lin</surname> <given-names>LI</given-names></name><name><surname>Yao</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>CC</given-names></name><name><surname>Huang</surname> <given-names>SY</given-names></name><name><surname>Ko</surname> <given-names>BS</given-names></name><name><surname>Hsu</surname> <given-names>SC</given-names></name><name><surname>Lin</surname> <given-names>CT</given-names></name><name><surname>Wu</surname> <given-names>SJ</given-names></name><name><surname>Chen</surname> <given-names>CY</given-names></name><name><surname>Tsay</surname> <given-names>W</given-names></name><name><surname>Chuang</surname> <given-names>EY</given-names></name><name><surname>Chou</surname> <given-names>WC</given-names></name><name><surname>Tien</surname> <given-names>HF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia</article-title><source>Blood Cancer Journal</source><volume>7</volume><elocation-id>663</elocation-id><pub-id pub-id-type="doi">10.1038/s41408-017-0022-y</pub-id><pub-id pub-id-type="pmid">29288251</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Lelij</surname> <given-names>P</given-names></name><name><surname>Godthelp</surname> <given-names>BC</given-names></name><name><surname>van Zon</surname> <given-names>W</given-names></name><name><surname>van Gosliga</surname> <given-names>D</given-names></name><name><surname>Oostra</surname> <given-names>AB</given-names></name><name><surname>Steltenpool</surname> <given-names>J</given-names></name><name><surname>de Groot</surname> <given-names>J</given-names></name><name><surname>Scheper</surname> <given-names>RJ</given-names></name><name><surname>Wolthuis</surname> <given-names>RM</given-names></name><name><surname>Waisfisz</surname> <given-names>Q</given-names></name><name><surname>Darroudi</surname> <given-names>F</given-names></name><name><surname>Joenje</surname> <given-names>H</given-names></name><name><surname>de Winter</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The cellular phenotype of roberts syndrome fibroblasts as revealed by ectopic expression of ESCO2</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e6936</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006936</pub-id><pub-id pub-id-type="pmid">19738907</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Lelij</surname> <given-names>P</given-names></name><name><surname>Lieb</surname> <given-names>S</given-names></name><name><surname>Jude</surname> <given-names>J</given-names></name><name><surname>Wutz</surname> <given-names>G</given-names></name><name><surname>Santos</surname> <given-names>CP</given-names></name><name><surname>Falkenberg</surname> <given-names>K</given-names></name><name><surname>Schlattl</surname> <given-names>A</given-names></name><name><surname>Ban</surname> <given-names>J</given-names></name><name><surname>Schwentner</surname> <given-names>R</given-names></name><name><surname>Hoffmann</surname> <given-names>T</given-names></name><name><surname>Kovar</surname> <given-names>H</given-names></name><name><surname>Real</surname> <given-names>FX</given-names></name><name><surname>Waldman</surname> <given-names>T</given-names></name><name><surname>Pearson</surname> <given-names>MA</given-names></name><name><surname>Kraut</surname> <given-names>N</given-names></name><name><surname>Peters</surname> <given-names>JM</given-names></name><name><surname>Zuber</surname> <given-names>J</given-names></name><name><surname>Petronczki</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Synthetic lethality between the cohesin subunits <italic>STAG1</italic> and <italic>STAG2</italic> in diverse Cancer contexts</article-title><source>eLife</source><volume>6</volume><elocation-id>e26980</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.26980</pub-id><pub-id pub-id-type="pmid">28691904</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vian</surname> <given-names>L</given-names></name><name><surname>PÄkowska</surname> <given-names>A</given-names></name><name><surname>Rao</surname> <given-names>SSP</given-names></name><name><surname>Kieffer-Kwon</surname> <given-names>KR</given-names></name><name><surname>Jung</surname> <given-names>S</given-names></name><name><surname>Baranello</surname> <given-names>L</given-names></name><name><surname>Huang</surname> <given-names>SC</given-names></name><name><surname>El Khattabi</surname> <given-names>L</given-names></name><name><surname>Dose</surname> <given-names>M</given-names></name><name><surname>Pruett</surname> <given-names>N</given-names></name><name><surname>Sanborn</surname> <given-names>AL</given-names></name><name><surname>Canela</surname> <given-names>A</given-names></name><name><surname>Maman</surname> <given-names>Y</given-names></name><name><surname>Oksanen</surname> <given-names>A</given-names></name><name><surname>Resch</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Lee</surname> <given-names>B</given-names></name><name><surname>Kovalchuk</surname> <given-names>AL</given-names></name><name><surname>Tang</surname> <given-names>Z</given-names></name><name><surname>Nelson</surname> <given-names>S</given-names></name><name><surname>Di Pierro</surname> <given-names>M</given-names></name><name><surname>Cheng</surname> <given-names>RR</given-names></name><name><surname>Machol</surname> <given-names>I</given-names></name><name><surname>St Hilaire</surname> <given-names>BG</given-names></name><name><surname>Durand</surname> <given-names>NC</given-names></name><name><surname>Shamim</surname> <given-names>MS</given-names></name><name><surname>Stamenova</surname> <given-names>EK</given-names></name><name><surname>Onuchic</surname> <given-names>JN</given-names></name><name><surname>Ruan</surname> <given-names>Y</given-names></name><name><surname>Nussenzweig</surname> <given-names>A</given-names></name><name><surname>Levens</surname> <given-names>D</given-names></name><name><surname>Aiden</surname> <given-names>EL</given-names></name><name><surname>Casellas</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The energetics and physiological impact of cohesin extrusion</article-title><source>Cell</source><volume>173</volume><fpage>1165</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.072</pub-id><pub-id pub-id-type="pmid">29706548</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viny</surname> <given-names>AD</given-names></name><name><surname>Ott</surname> <given-names>CJ</given-names></name><name><surname>Spitzer</surname> <given-names>B</given-names></name><name><surname>Rivas</surname> <given-names>M</given-names></name><name><surname>Meydan</surname> <given-names>C</given-names></name><name><surname>Papalexi</surname> <given-names>E</given-names></name><name><surname>Yelin</surname> <given-names>D</given-names></name><name><surname>Shank</surname> <given-names>K</given-names></name><name><surname>Reyes</surname> <given-names>J</given-names></name><name><surname>Chiu</surname> <given-names>A</given-names></name><name><surname>Romin</surname> <given-names>Y</given-names></name><name><surname>Boyko</surname> <given-names>V</given-names></name><name><surname>Thota</surname> <given-names>S</given-names></name><name><surname>Maciejewski</surname> <given-names>JP</given-names></name><name><surname>Melnick</surname> <given-names>A</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Levine</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis</article-title><source>Journal of Experimental Medicine</source><volume>212</volume><fpage>1819</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1084/jem.20151317</pub-id><pub-id pub-id-type="pmid">26438361</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viny</surname> <given-names>AD</given-names></name><name><surname>Levine</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cohesin mutations in myeloid malignancies made simple</article-title><source>Current Opinion in Hematology</source><volume>25</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1097/MOH.0000000000000405</pub-id><pub-id pub-id-type="pmid">29278534</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldman</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Emerging themes in cohesin Cancer biology</article-title><source>Nature Reviews Cancer</source><volume>20</volume><fpage>504</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1038/s41568-020-0270-1</pub-id><pub-id pub-id-type="pmid">32514055</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Krivtsov</surname> <given-names>AV</given-names></name><name><surname>Sinha</surname> <given-names>AU</given-names></name><name><surname>North</surname> <given-names>TE</given-names></name><name><surname>Goessling</surname> <given-names>W</given-names></name><name><surname>Feng</surname> <given-names>Z</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML</article-title><source>Science</source><volume>327</volume><fpage>1650</fpage><lpage>1653</lpage><pub-id pub-id-type="doi">10.1126/science.1186624</pub-id><pub-id pub-id-type="pmid">20339075</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>CW</given-names></name><name><surname>Purkayastha</surname> <given-names>A</given-names></name><name><surname>Jones</surname> <given-names>KT</given-names></name><name><surname>Thaker</surname> <given-names>SK</given-names></name><name><surname>Banerjee</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>In vivo genetic dissection of tumor growth and the warburg effect</article-title><source>eLife</source><volume>5</volume><elocation-id>e18126</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.18126</pub-id><pub-id pub-id-type="pmid">27585295</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendt</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Resolving the genomic localization of the kollerin Cohesin-Loader complex</article-title><source>Methods in Molecular Biology</source><volume>1515</volume><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-6545-8_7</pub-id><pub-id pub-id-type="pmid">27797076</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Westerfield</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1995">1995</year><source>The Zebrafish Book. a Guide for the Laboratory Use of Zebrafish (Brachydanio rerio)</source><publisher-name>University of Oregon Press</publisher-name></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wutz</surname> <given-names>G</given-names></name><name><surname>VÃ¡rnai</surname> <given-names>C</given-names></name><name><surname>Nagasaka</surname> <given-names>K</given-names></name><name><surname>Cisneros</surname> <given-names>DA</given-names></name><name><surname>Stocsits</surname> <given-names>RR</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Schoenfelder</surname> <given-names>S</given-names></name><name><surname>Jessberger</surname> <given-names>G</given-names></name><name><surname>Muhar</surname> <given-names>M</given-names></name><name><surname>Hossain</surname> <given-names>MJ</given-names></name><name><surname>Walther</surname> <given-names>N</given-names></name><name><surname>Koch</surname> <given-names>B</given-names></name><name><surname>Kueblbeck</surname> <given-names>M</given-names></name><name><surname>Ellenberg</surname> <given-names>J</given-names></name><name><surname>Zuber</surname> <given-names>J</given-names></name><name><surname>Fraser</surname> <given-names>P</given-names></name><name><surname>Peters</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Topologically associating domains and chromatin loops depend on cohesin and are regulated by CTCF, WAPL, and PDS5 proteins</article-title><source>The EMBO Journal</source><volume>36</volume><fpage>3573</fpage><lpage>3599</lpage><pub-id pub-id-type="doi">10.15252/embj.201798004</pub-id><pub-id pub-id-type="pmid">29217591</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wutz</surname> <given-names>G</given-names></name><name><surname>Ladurner</surname> <given-names>R</given-names></name><name><surname>St Hilaire</surname> <given-names>BG</given-names></name><name><surname>Stocsits</surname> <given-names>RR</given-names></name><name><surname>Nagasaka</surname> <given-names>K</given-names></name><name><surname>Pignard</surname> <given-names>B</given-names></name><name><surname>Sanborn</surname> <given-names>A</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>VÃ¡rnai</surname> <given-names>C</given-names></name><name><surname>Ivanov</surname> <given-names>MP</given-names></name><name><surname>Schoenfelder</surname> <given-names>S</given-names></name><name><surname>van der Lelij</surname> <given-names>P</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name><name><surname>DÃ¼rnberger</surname> <given-names>G</given-names></name><name><surname>Roitinger</surname> <given-names>E</given-names></name><name><surname>Mechtler</surname> <given-names>K</given-names></name><name><surname>Davidson</surname> <given-names>IF</given-names></name><name><surname>Fraser</surname> <given-names>P</given-names></name><name><surname>Lieberman-Aiden</surname> <given-names>E</given-names></name><name><surname>Peters</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ESCO1 and CTCF enable formation of long chromatin loops by protecting cohesin<sup>STAG1</sup> from WAPL</article-title><source>eLife</source><volume>9</volume><elocation-id>e52091</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.52091</pub-id><pub-id pub-id-type="pmid">32065581</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Yan</surname> <given-names>Y</given-names></name><name><surname>Deb</surname> <given-names>S</given-names></name><name><surname>Rangasamy</surname> <given-names>D</given-names></name><name><surname>Germann</surname> <given-names>M</given-names></name><name><surname>Malaterre</surname> <given-names>J</given-names></name><name><surname>Eder</surname> <given-names>NC</given-names></name><name><surname>Ward</surname> <given-names>RL</given-names></name><name><surname>Hawkins</surname> <given-names>NJ</given-names></name><name><surname>Tothill</surname> <given-names>RW</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Mortensen</surname> <given-names>NJ</given-names></name><name><surname>Fox</surname> <given-names>SB</given-names></name><name><surname>McKay</surname> <given-names>MJ</given-names></name><name><surname>Ramsay</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cohesin Rad21 mediates loss of heterozygosity and is upregulated via wnt promoting transcriptional dysregulation in gastrointestinal tumors</article-title><source>Cell Reports</source><volume>9</volume><fpage>1781</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.10.059</pub-id><pub-id pub-id-type="pmid">25464844</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname> <given-names>K</given-names></name><name><surname>Toki</surname> <given-names>T</given-names></name><name><surname>Okuno</surname> <given-names>Y</given-names></name><name><surname>Kanezaki</surname> <given-names>R</given-names></name><name><surname>Shiraishi</surname> <given-names>Y</given-names></name><name><surname>Sato-Otsubo</surname> <given-names>A</given-names></name><name><surname>Sanada</surname> <given-names>M</given-names></name><name><surname>Park</surname> <given-names>M-ja</given-names></name><name><surname>Terui</surname> <given-names>K</given-names></name><name><surname>Suzuki</surname> <given-names>H</given-names></name><name><surname>Kon</surname> <given-names>A</given-names></name><name><surname>Nagata</surname> <given-names>Y</given-names></name><name><surname>Sato</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>R</given-names></name><name><surname>Shiba</surname> <given-names>N</given-names></name><name><surname>Chiba</surname> <given-names>K</given-names></name><name><surname>Tanaka</surname> <given-names>H</given-names></name><name><surname>Hama</surname> <given-names>A</given-names></name><name><surname>Muramatsu</surname> <given-names>H</given-names></name><name><surname>Hasegawa</surname> <given-names>D</given-names></name><name><surname>Nakamura</surname> <given-names>K</given-names></name><name><surname>Kanegane</surname> <given-names>H</given-names></name><name><surname>Tsukamoto</surname> <given-names>K</given-names></name><name><surname>Adachi</surname> <given-names>S</given-names></name><name><surname>Kawakami</surname> <given-names>K</given-names></name><name><surname>Kato</surname> <given-names>K</given-names></name><name><surname>Nishimura</surname> <given-names>R</given-names></name><name><surname>Izraeli</surname> <given-names>S</given-names></name><name><surname>Hayashi</surname> <given-names>Y</given-names></name><name><surname>Miyano</surname> <given-names>S</given-names></name><name><surname>Kojima</surname> <given-names>S</given-names></name><name><surname>Ito</surname> <given-names>E</given-names></name><name><surname>Ogawa</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The landscape of somatic mutations in down syndromeârelated myeloid disorders</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1293</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1038/ng.2759</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>LG</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>He</surname> <given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS: A Journal of Integrative Biology</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G</given-names></name><name><surname>He</surname> <given-names>QY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization</article-title><source>Molecular BioSystems</source><volume>12</volume><fpage>477</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1039/C5MB00663E</pub-id><pub-id pub-id-type="pmid">26661513</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaremba</surname> <given-names>T</given-names></name><name><surname>Curtin</surname> <given-names>NJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>PARP inhibitor development for systemic Cancer targeting</article-title><source>Anti-Cancer Agents in Medicinal Chemistry</source><volume>7</volume><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.2174/187152007781668715</pub-id><pub-id pub-id-type="pmid">17896912</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.61405.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Majeti</surname><given-names>Ravi</given-names></name><role>Reviewing Editor</role><aff><institution>Stanford University</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Viny</surname><given-names>Aaron</given-names> </name><role>Reviewer</role></contrib><contrib contrib-type="reviewer"><name><surname>Valentina</surname><given-names>Massa</given-names> </name><role>Reviewer</role><aff><institution>UniversitÃ  degli Studi di Milano</institution><country>Italy</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The manuscript describes an interesting finding that stimulation of Wnt signaling can lead to lethality in cohesin mutant cells. This suggests a potentially novel therapeutic strategy for cohesion-mutant cancers.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Cohesin mutations are synthetic lethal with stimulation of WNT signaling&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Richard White as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Aaron Viny (Reviewer #2); Massa Valentina (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in <italic>eLife</italic> but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.</p><p>Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in <italic>eLife</italic>, either of which would be linked to the original paper.</p><p>Summary:</p><p>In this manuscript, Chin et al., investigate synthetic lethal candidates in conjunction with cohesin mutations in cancer. The authors engineer mutant cell line variants for several members of the cohesin complex and demonstrate that they exhibit established features of cohesin-mutant cells. Then they conduct a small molecule screen to identify compounds and pathways with increased sensitivity in these cohesin-mutant cells. They identify a GSK3 inhibitor suggesting that Wnt pathway activation is synthetic lethal with cohesin mutants. They show evidence suggesting this occurs though Î²-catenin stabilization and activation of Wnt target genes. Finally, they use a genetic zebrafish model to show hyperactivation of Wnt pathway in Rad21-deficient embryos. In general, the link between cohesin mutants and Wnt pathway activation is of interest, but there are several issues with the manuscript.</p><p>Essential revisions:</p><p>1) While there is evidence presented here that cohesin-mutant cells exhibit increased Wnt pathway activation, there is no data demonstrating that it is key to the cancer phenotypes of cohesin-mutant cancers. Such data would enhance the significance of the findings here.</p><p>2) Analysis of the cohesin-mutant MCF10A clones relied on investigation of a single clone per gene. This is not sufficient to draw convincing conclusions, particularly with CRIPSR/Cas9 targeting and potential off target effects. Several clones per gene should be investigated to account for potential clonal variability, particularly given the differences in phenotypes observed between these clones.</p><p>3) The chemical screen identified a number of cohesin mutant sensitivities, and the common hits are shown, however, given the phenotypic differences between the RAD21/SMC3 clone and the STAG2 null clones in micronuclei and lagging strands, did the 76 STAG2 unique chemical compounds share a functional class? Why do the authors think SMC3 and STAG2 had far more overlap that each of these did with RAD21? Why did RAD21 have so few hits overall by comparison?</p><p>4) Western blotting shows cohesin mutant clones have increased total and membrane Î²-catenin that lead to transcriptional responses. Is there evidence of Wnt pathway/Î²-catenin transcriptional activation in publicly available datasets of cohesin perturbation or cohesin-mutant cancers?</p><p>5) The zebrafish experiments are fundamental and elegantly done. However, I think that, given the role of RAD21 and of the other cohesin subunits, it would be pivotal to include similar experiments with zebrafish modelling other genes of the complex.</p><p>6) Cohesin subunit deficient clones of MCF10A were generated using CRISPR-Cas9 editing. While this is clearly described in the Materials and methods section, it would be helpful to state the model system as well in results.</p><p>7) For cell cycle analysis (Results section) it would be extremely important, also considering the literature, to assess cell death rate.</p><p>8) In Figure 1F/1G/Figure 1âfigure supplement 1B what do the square symbols represent? Please include in the legend.</p><p>9) In Figure 4A/B/Figure 4âfigure supplement 1A/1B please include size markers. Also Figure 4âfigure supplement 1 needs a loading control such as tubulin.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.61405.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) While there is evidence presented here that cohesin-mutant cells exhibit increased Wnt pathway activation, there is no data demonstrating that it is key to the cancer phenotypes of cohesin-mutant cancers. Such data would enhance the significance of the findings here.</p></disp-quote><p>The reviewers make a good point. It would be ideal to test if cohesin mutant primary cancer cells are Wnt-sensitivity or hyperactivity as part of their phenotype, but actually testing this in vivo is quite a difficult task. Primary cells with and without cohesin mutations would need to be compared in a Wnt-stimulated scenario, because there may be no apparent phenotype to measure in cells at baseline or endpoint conditions where Wnt signalling is not active.</p><p>While we unfortunately do not have access to primary cells, in a revision experiment for this paper we managed to show that Wnt sensitivity is extendable to another cancer cell type (colorectal cancer cell line HCT116), and a different cohesin subunit mutation: <italic>SMC1A</italic>.</p><p>To provide the new data, we collaborated with our Italian colleague Antonio Musio, whose lab has the appropriate models. Antonioâs group have characterised two cohesin SMC1A mutations identified in human colorectal carcinomas, c.2027A&gt;G and c.2479 C&gt;T (Cucco et al., 2014; Sarogni et al., 2019). Using the same treatment conditions as we did for MCF10A cells, Antonioâs group showed increased b-catenin protein levels, particularly in response to LY2090314, in HCT116 cells that stably overexpress SMC1A containing these two different mutations. Importantly, SMC1A is a cohesin gene that wasnât tested in our screen or subjected to downstream analysis in our lab, and yet these experiments confirm our independent findings.</p><p>We have added a new figure supplement with these data (Figure 5âfigure supplement 2). Antonio and colleague Michela Pallotta (who performed the work) have been included as co-authors on the manuscript. The new text in the results (which also explains the modelâs limitation) is reproduced below:</p><p>âTo determine if stabilization of Î²-catenin is conserved in a second model of cohesin mutant cancer, we performed an identical LY2090314 treatment on HCT116 cells that were stably transfected to express two SMC1A mutations identified in human colorectal carcinomas, c.2027A&gt;G (leading to p.E676G change near the hinge domain) and c.2479 C&gt;T (leading to a truncated protein, p.Q827X) [53, 54]. The limitation is that these cells are not a model of cohesin deficiency, but rather, one in which normal cohesin function is perturbed by expression of a mutant version of SMC1A [54]. We observed an increased basal level of phosphorylated Î²-catenin at Ser675 in cells that express either of these SMC1A mutants. Furthermore, LY2090314 treatment markedly increased total Î²-catenin in both the SMC1A mutants compared with HCT116 wild type controls (Figure 5âfigure supplement 2A,B). The results indicate that abnormally high levels of active Î²-catenin are also present following Wnt stimulation when a fourth subunit of cohesin, SMC1A, is perturbed.â</p><p>Interestingly, the mutant SMC1A-expressing HCT116 cells are more aggressive in tumour formation (Sarogni et al., 2019). Future experiments beyond the scope of this study could follow up to determine if Wnt signalling is important for this phenotype.</p><p>Below in response to point #4, we describe an additional analysis of TCGA data, which supports the idea that cohesin mutant cancers have over-active Wnt signalling.</p><disp-quote content-type="editor-comment"><p>2) Analysis of the cohesin-mutant MCF10A clones relied on investigation of a single clone per gene. This is not sufficient to draw convincing conclusions, particularly with CRIPSR/Cas9 targeting and potential off target effects. Several clones per gene should be investigated to account for potential clonal variability, particularly given the differences in phenotypes observed between these clones.</p></disp-quote><p>Owing to the expense of high throughput screening, it was too costly to screen more than one clone per gene in the screen. However, even though thereâs only a single clone representing each cohesin subunit in the SL screen, we believe the screen was actually quite conservative and robust, because the top hits we followed up were only selected if they affected all three cohesin mutant clones.</p><p>However, in response to this valid comment, we have now analysed one additional RAD21 and one addition SMC3 clone that were produced, but not used in the screen. These clones (RAD21+/- clone 2 and SMC3 +/- clone 2) behave similarly to the original clones that were used in the screen. Data showing allele details, cell morphology, mRNA levels, chromosome cohesion defects, cell viability, growth curves and response to LY2090314 are shown in Figure 3âfigure supplement 3. The cells grow slightly more slowly than wild type and are differentially sensitive to LY2090314. These results indicate that the clones used for the screen were likely to be typical and any variability was not likely to be due to off-target effects. The new data are described in the Results section:</p><p>âCollectively, characterization of our cohesin-deficient clones provided confidence that they represent suitable models for synthetic lethal screening. To confirm that the phenotypes of our chosen clones are representative, we selected a further two clones with heterozygous deletions in SMC3 and RAD21, and monitored their growth, morphology and chromosome cohesion (Figure 3âfigure supplement 3). These analyses showed that the two additional deletion clones were similar to those already characterized (Figure 1, Figure 2, Figure 3), providing surety that our cohesin-deficient cell lines have properly representative phenotypes. Furthermore, none of the cohesin-deficient clones exhibited enhanced cell death compared with parental MCF10A cells (Figure 2B; Figure 3âfigure supplement 3).â</p><p>Regarding the subtly different phenotypes of the cohesin-deficient clones, it is perhaps not surprising that the clones do not have identical phenotypes, particularly for the <italic>STAG2</italic> homozygous deletion.</p><p>First, STAG2 can be substituted by STAG1 and therefore a <italic>STAG2</italic> mutation can be homozygous, unlike SMC3 and RAD21. This means that in the <italic>STAG2</italic> mutant, STAG1 cohesin is predominant, whereas in <italic>RAD21</italic> and <italic>SMC3</italic> mutants, there would be predicted to be a reduction in dose of STAG1- and STAG2-containing cohesin.</p><p>Second, differences in chromosome segregation phenotypes between the different cohesin-deficient clones might be due to STAG2 having a role in centromere chromosome cohesion (Canudas and Smith, 2009) such that its homozygous loss results in âcleanerâ mis-segregation events and more frequent complete loss of chromosome cohesion, as shown in Figure 2D (please note that the key of Figure 2D has been corrected to show that the black section of the bar is 'normal' and the 'green' sections correspond to loss of cohesion!).</p><p>The functional differences between STAG2 and STAG1 cohesin are described nicely in a recent review from Ana Losada and colleagues (Cuadrado and Losada, 2020).</p><p>In the screen there was quite a high degree of overlap of hits for the clones we generated, particularly <italic>SMC3</italic> and <italic>RAD21</italic>, where only 5 of 27 compounds affecting <italic>RAD21</italic> mutants were not also a hit in <italic>SMC3</italic> mutants, and only 1 hit that was exclusive to <italic>RAD21</italic>. This suggests that despite potential differences between the clones, there were a number of common sensitivities. All clones have been well characterised, and findings extended to other cell lines and zebrafish.</p><disp-quote content-type="editor-comment"><p>3) The chemical screen identified a number of cohesin mutant sensitivities, and the common hits are shown, however, given the phenotypic differences between the RAD21/SMC3 clone and the STAG2 null clones in micronuclei and lagging strands, did the 76 STAG2 unique chemical compounds share a functional class?</p></disp-quote><p>The unique hits for each clone are given in Figure 4âfigure supplement 2. This figure shows that functional classes are largely shared among the cohesin subunits. From this figure, classes of compound that affected only cells containing the <italic>STAG2</italic> mutation can be identified. These include âcytoskeletalâ, âGPCR and G proteinâ, âImmunology and inflammationâ and âtransmembrane transportersâ. These extra categories specific to <italic>STAG2</italic> mutation look like they reflect a response to particular signalling pathways, and could result from the more specialised role of STAG2-cohesin in tissue-specific transcription.</p><disp-quote content-type="editor-comment"><p>Why do the authors think SMC3 and STAG2 had far more overlap that each of these did with RAD21?</p></disp-quote><p>Figure 4E shows that a number of compounds affecting <italic>RAD21</italic> mutant cells also inhibited <italic>SMC3</italic> mutants (n=4) and <italic>STAG2</italic> mutants (n=4), and there were 18 hits in common with all 3 mutants. In addition, <italic>RAD21</italic> mutant cells were sensitive to only one compound that didnât also affect the other mutants, and this particular compound is involved in DNA damage repair. Itâs just that there were fewer compounds overall that affected <italic>RAD21</italic> mutants. Thatâs probably why there wasnât as much overlap as observed with <italic>SMC3</italic> and <italic>STAG2</italic>.</p><disp-quote content-type="editor-comment"><p>Why did RAD21 have so few hits overall by comparison?</p></disp-quote><p>Thatâs a very good question. We donât have an answer but can speculate that additional compound sensitivities in <italic>SMC3</italic> and <italic>STAG2</italic> mutants might derive from important dose-dependent functions that they have in the nucleus, which are not equally sensitised by limiting the amount of RAD21-containing cohesin. We wonder if SMC3 depletion exposes an important role in chromosome maintenance because of our observation of increased nuclear decompaction and micronuclei the <italic>SMC3</italic> mutant clone (Figure 2E-G). The specialised role of STAG2 in gene expression (see answer to Q2 above) might give the STAG2 mutant an increased drug sensitivity profile that includes a wider range of pathways.</p><disp-quote content-type="editor-comment"><p>4) Western blotting shows cohesin mutant clones have increased total and membrane Î²-catenin that lead to transcriptional responses. Is there evidence of Wnt pathway/Î²-catenin transcriptional activation in publicly available datasets of cohesin perturbation or cohesin-mutant cancers?</p></disp-quote><p>This is an excellent suggestion, we have followed this up bioinformatically using publicly available TCGA data. We could only really look at <italic>STAG2-</italic>mutant cancers with high sample numbers in TCGA, because we needed a decent number of samples that had a cohesin mutation AND gene expression data. Hereâs a summary of what we did:</p><p><italic>STAG2</italic> nonsense mutations (frameshift or stop-gained events) with gene expression were retrieved from TCGA by cancer type. Only cancer types having more than two <italic>STAG2</italic> nonsense mutation samples were considered. After this filtering, four cancer types are remaining: Bladder Urothelial Carcinoma (BLCA), Uterine Corpus Endometrial Carcinoma (UCEC), Glioblastoma multiforme (GBM) and Cervical Kidney renal papillary cell carcinoma (KIRP).</p><p>For each cancer type, an equal number of control samples were also retrieved. Samples were considered as control if no STAG2 nonsense mutation was present.</p><p>When the 150 samples (all cancer type) were ranked by the Wald statistic, STAG2 was the first ranked gene. The comparison of this ranking to the gene set HALLMARK_WNT_Î_CATENIN ranked this pathway as 8th most enriched, overall showing an enrichment in up-regulated genes in the Wnt pathway. The results can be found in Supplementary file 2.</p><p>So, in the analysis we did, it looks like Wnt hyperactivation IS a feature of STAG2 mutant cancers. However, we treat the results quite cautiously, and only in the Discussion section, because of the caveats with this approach:</p><p>âIs Wnt pathway activation a conserved feature of cohesin-mutant cancers? Using publicly available data at TCGA [74], we correlated expression of genes in the Wnt pathway (Hallmark WNT Î²-catenin signaling) with nonsense mutation of STAG2, the most common of the cohesin mutations, in the four most represented cancers (bladder cancer, endometrial carcinoma, glioblastoma multiforme and cervical kidney renal papillary cell carcinoma). In comparative ranking, the Wnt pathway ranks 8th for enrichment in upregulated genes (after DNA repair/G2 checkpoint, MYC/E2F targets, oxidative phosphorylation and the unfolded protein response; Supplementary File 2). While our analysis could indicate conserved upregulation of the Wnt pathway in STAG2 mutant cancers, a caveat is that the true situation is likely to be more complex. If Î²-catenin is stabilized, upstream and in-parallel effectors such as Wnt ligands, receptors, signalling intermediates might trend to downregulation owing to negative feedback loop regulation of the Wnt pathway for example via DKK1 [75]. Furthermore, because cancer collections are unlikely to be under Wnt stimulation at the time of RNA collection, it is possible that their true Wnt sensitivity will be missed in a steady-state transcription analysis.â</p><disp-quote content-type="editor-comment"><p>5) The zebrafish experiments are fundamental and elegantly done. However, I think that, given the role of RAD21 and of the other cohesin subunits, it would be pivotal to include similar experiments with zebrafish modelling other genes of the complex.</p></disp-quote><p>We are happy to include timely new data that addresses this concern.</p><p>We recently generated zebrafish carrying mutations for the <italic>stag</italic> genes, <italic>stag1a</italic>, <italic>stag1b</italic> and <italic>stag2b</italic>. Characterisation of the Stag paralogues in zebrafish indicates that Stag2b is the most abundant Stag2, and likely to be most closely related to human STAG2. A description of the mutants and their early haematopoietic phenotypes has recently been accepted for publication (preprint here: https://www.biorxiv.org/content/10.1101/2020.10.19.346122v1).</p><p>The <italic>stag2b</italic> mutant is homozygous viable. We crossed this mutant to the TCF reporter line then crossed these fish (<italic>stag2b</italic>/+; TCF/+) to <italic>stag2b</italic>/+. Progeny carrying the TCF reporter were stimulated (or not) with LiCl, imaged, and genotyped post-imaging. Data for (<italic>stag2b</italic>/<italic>stag2b</italic>; TCF/+) and (+/+; TCF/+) genotypes were collected for a revision to Figure 6, now Figure 7 in the manuscript.</p><p>The results show higher baseline activity of the TCF Wnt reporter in <italic>stag2b</italic> homozygotes, but when stimulated with LiCl, we could not reliably determine extra expression above WT. Therefore, the <italic>stag2b</italic> mutant zebrafish also show enhanced Wnt signalling, but unlike for <italic>rad21-/-</italic> embryos, the enhancement is at baseline, pre-stimulation. Overall, the zebrafish experiments are consistent with over-active Wnt signalling being associated with cohesin mutation during embryogenesis. This information has been added to the Results:</p><p>âZebrafish embryos heterozygous for Tg(7xTCF-Xla.Siam:nslmCherry)ia5, and either homozygous for stag2bnz207, rad21nz171 or wild type, were exposed to 0.15 M LiCl, an agonist of the Wnt signaling pathway (Figure 7). Expression of mCherry in the midbrain of embryos was detected at 20 hours post-fertilization (hpf) by epifluorescence and confocal imaging. A constitutive low level of mCherry is present in the developing midbrain of both untreated wild type (Figure 7A,B,I,J), and rad21nz171 embryos (Figure 7M,N). On the other hand, untreated stag2bnz207 embryos exhibited noticeably higher basal mCherry levels than wild type siblings (Figure 7E,F compared with A,B). This observation indicates that the Wnt pathway is more intrinsically active in these embryos. However, the addition of LiCl did not result in much additional fluorescence owing to stag2bnz207 mutation (Figure 7G,H compared with C,D). While mCherry expression in rad21nz171 mutants resembled that in wild type embryos at baseline, LiCl treatment dramatically increased the existing midbrain mCherry expression in rad21nz171 mutants compared with wild type embryos (Figure 7O,P compared with K,L). This observation indicates that rad21nz171 mutants are more sensitive to Wnt stimulation than wild type.â</p><p>Anastasia Labudina, who performed these experiments, has been added as an author on the manuscript.</p><disp-quote content-type="editor-comment"><p>6) Cohesin subunit deficient clones of MCF10A were generated using CRISPR-Cas9 editing. While this is clearly described in the Materials and methods section, it would be helpful to state the model system as well in results.</p></disp-quote><p>A brief description has been added to subsection âCohesin gene deletion in MCF10A cells results in minor cell cycle defectsâ, and Supplementary file 1 has been redesignated as a Figure (Figure 1) describing generation of the mutant clones.</p><disp-quote content-type="editor-comment"><p>7) For cell cycle analysis (Results section) it would be extremely important, also considering the literature, to assess cell death rate.</p></disp-quote><p>We have included trypan blue measurement of cell survival in Figure 3âfigure supplement 3E, described in the text: <italic>â</italic>Furthermore, none of the cohesin-deficient clones exhibited enhanced cell death compared with parental MCF10A cells (Figure 2B; Figure 3âfigure supplement 3E).â</p><p>None of the cohesin-deficient clones have particularly enhanced cell death. Cell survival information is already included in the paper: the cell cycle flow cytometry analyses in Figure 2B do not show a sub-G1 population, which would be indicative of cell death.</p><disp-quote content-type="editor-comment"><p>8) In Figure 1F/1G/Figure 1âfigure supplement 1B what do the square symbols represent? Please include in the legend.</p></disp-quote><p>This Figure is now Figure 2. The square symbols refer to the biological replicates for each experiment. There were actually 5 biological replicates per experiment, and this has now been corrected in the figure legend for both figures.</p><disp-quote content-type="editor-comment"><p>9) In Figure 4A/B/Figure 4âfigure supplement 1A/1B please include size markers. Also Figure 4âfigure supplement 1 needs a loading control such as tubulin.</p></disp-quote><p>This Figure is now Figure 5. For Figure 5A,B, we have provided a file showing the original blots with molecular size markers as Figure 5âsource data 1. A loading control and molecular sizing has been added to Figure 5âfigure supplement 1A/B. Original blots with molecular sizes have been provided for Figure 5âfigure supplement 1 (Figure 5âsource data 3) and Figure 5âfigure supplement 2 (Figure 5âsource data 4).</p></body></sub-article></article>